

IGFBP3 Repression Driven by Inflammation links Air Pollution to Placental and Developmental defects

Sunil Singh, Isha Goel, Anubhuti Rana, Anamta Gul, Javed Quadri, Asit Mridha, Lakshay Malhotra, Neha Kashyap, Baburajan Radha, Arnab Nayek, Swati Ajmeriya, Jitender Prasad, Ruby Dhar, and Subhradip Karmakar

Corresponding author(s): Subhradip Karmakar (subhradip.k@aiims.edu) , Ruby Dhar (rubydhar@aiims.edu)

Review Timeline:

Submission Date:	10th Sep 25
Editorial Decision:	24th Oct 25
Revision Received:	29th Dec 25
Editorial Decision:	21st Jan 26
Revision Received:	17th Feb 26
Accepted:	20th Feb 26

Editor: Zeljko Durdevic

Transaction Report:

(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. Depending on transfer agreements, referee reports obtained elsewhere may or may not be included in this compilation. Referee reports are anonymous unless the Referee chooses to sign their reports.)

24th Oct 2025

Dear Prof. Karmakar,

Thank you for the submission of your manuscript to EMBO Molecular Medicine. We have now received feedback from the two reviewers who agreed to evaluate your manuscript. Both referees recognize interest of the study but also raise important concerns that should be addressed in a major revision. If you would like to discuss further the points raised by the referees, I am available to do so via email or video. Let me know if you are interested in this option.

Further consideration of a revision that addresses reviewers' concerns in full will entail a second round of review. EMBO Molecular Medicine encourages a single round of revision only and therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript. For this reason, and to save you from any frustrations in the end, I would strongly advise against returning an incomplete revision.

We would welcome the submission of a revised version within three months for further consideration. Please let us know if you require longer to complete the revision.

I look forward to receiving your revised manuscript.

Yours sincerely,

Zeljko Durdevic

Zeljko Durdevic
Senior Editor
EMBO Molecular Medicine

When submitting your revised manuscript, please carefully review the instructions that follow below. We perform an initial quality control of all revised manuscripts before re-review; failure to include requested items will delay the evaluation of your revision.

We require:

- 1) A .docx formatted version of the manuscript text (including legends for main figures, EV figures and tables). Please make sure that the changes are highlighted to be clearly visible.
- 2) Individual production quality figure files as .eps, .tif, .jpg (one file per figure). For guidance, download the 'Figure Guide PDF': (<https://www.embopress.org/page/journal/17574684/authorguide#figureformat>).
- 3) A .docx formatted letter INCLUDING the reviewers' reports and your detailed point-by-point responses to their comments. As part of the EMBO Press transparent editorial process, the point-by-point response is part of the Review Process File (RPF), which will be published alongside your paper.
- 4) A complete author checklist, which you can download from our author guidelines (<https://www.embopress.org/page/journal/17574684/authorguide#submissionofrevisions>). Please insert information in the checklist that is also reflected in the manuscript. The completed author checklist will also be part of the RPF.
- 5) Please note that all corresponding authors are required to supply an ORCID ID for their name upon submission of a revised manuscript.
- 6) It is mandatory to include a 'Data Availability' section after the Materials and Methods. Before submitting your revision, primary datasets produced in this study need to be deposited in an appropriate public database, and the accession numbers and

database listed under 'Data Availability'. Please remember to provide a reviewer password if the datasets are not yet public (see <https://www.embopress.org/page/journal/17574684/authorguide#dataavailability>).

In case you have no data that requires deposition in a public database, please state so in this section. Note that the Data Availability Section is restricted to new primary data that are part of this study.

7) For data quantification: please specify the name of the statistical test used to generate error bars and P values, the number (n) of independent experiments (specify technical or biological replicates) underlying each data point and the test used to calculate p-values in each figure legend. The figure legends should contain a basic description of n, P and the test applied. Graphs must include a description of the bars and the error bars (s.d., s.e.m.). See also 'Figure Legend' guidelines: <https://www.embopress.org/page/journal/17574684/authorguide#figureformat>

8) At EMBO Press we ask authors to provide source data for the main manuscript figures. You will receive a separate email with instructions for providing source data with your revised manuscript, including how to upload and organize the files.

9) Our journal encourages inclusion of *data citations in the reference list* to directly cite datasets that were re-used and obtained from public databases. Data citations in the article text are distinct from normal bibliographical citations and should directly link to the database records from which the data can be accessed. In the main text, data citations are formatted as follows: "Data ref: Smith et al, 2001" or "Data ref: NCBI Sequence Read Archive PRJNA342805, 2017". In the Reference list, data citations must be labeled with "[DATASET]". A data reference must provide the database name, accession number/identifiers and a resolvable link to the landing page from which the data can be accessed at the end of the reference. Further instructions are available at .

10) We replaced Supplementary Information with Expanded View (EV) Figures and Tables that are collapsible/expandable online. A maximum of 5 EV Figures can be typeset. EV Figures should be cited as 'Figure EV1, Figure EV2' etc... in the text and their respective legends should be included in the main text after the legends of regular figures.

- For the figures that you do NOT wish to display as Expanded View figures, they should be bundled together with their legends in a single PDF file called *Appendix*, which should start with a short Table of Content. Appendix figures should be referred to in the main text as: "Appendix Figure S1, Appendix Figure S2" etc.

- Additional Tables/Datasets should be labeled and referred to as Table EV1, Dataset EV1, etc. Legends have to be provided in a separate tab in case of .xls files. Alternatively, the legend can be supplied as a separate text file (README) and zipped together with the Table/Dataset file.

See detailed instructions here:

.

11) The paper explained: EMBO Molecular Medicine articles are accompanied by a summary of the articles to emphasize the major findings in the paper and their medical implications for the non-specialist reader. Please provide a draft summary of your article highlighting

- the medical issue you are addressing,
- the results obtained and
- their clinical impact.

This may be edited to ensure that readers understand the significance and context of the research. Please refer to any of our published articles for an example.

12) Author contributions: You will be asked to provide CRediT (Contributor Role Taxonomy) terms in the submission system. These replace a narrative author contribution section in the manuscript.

13) A Conflict of Interest statement should be provided in the main text.

14) Every published paper now includes a 'Synopsis' to further enhance discoverability. Synopses are displayed on the journal webpage and are freely accessible to all readers. They include a short stand first (maximum of 300 characters, including space) as well as 2-5 one-sentences bullet points that summarizes the paper. Please write the bullet points to summarize the key NEW findings. They should be designed to be complementary to the abstract - i.e. not repeat the same text. We encourage inclusion of key acronyms and quantitative information (maximum of 30 words / bullet point). Please use the passive voice. Please attach these in a separate file or send them by email, we will incorporate them accordingly.

Please also suggest a striking image or visual abstract to illustrate your article as a PNG file 550 px wide x 300-600 px high.

15) Include a Reagents and Tools Table as part of the Methods section, which can be downloaded from our author guidelines (<https://www.embopress.org/page/journal/17574684/authorguide#structuredmethods>)

EMBO Molecular Medicine has a "scooping protection" policy, whereby similar findings that are published by others during review or revision are not a criterion for rejection. Should you decide to submit a revised version, I do ask that you get in touch after three months if you have not completed it, to update us on the status.

***** Reviewer's comments *****

Referee #1 (Comments on Novelty/Model System for Author):

Model system should be justified more carefully and be discussed in the context of a human pregnancy. Strengths and shortcomings of different model systems has to be discussed.

Referee #1 (Remarks for Author):

This study addresses a critical topic in environmental health, specifically the impact of particulate matter (PM) on pregnancy and fetal outcomes. The focus on the placenta as a critical organ and its susceptibility to environmental pollutants is highly relevant to the journal's scope, which emphasizes molecular mechanisms in health and disease. The methods are scientifically sound, employ standard techniques, and are appropriate for addressing the study's objectives.

Study presents a comprehensive dataset from in vitro, ex vivo, in vivo, and epidemiological studies to elucidate how urban particulate matter (UPM) exposure impairs placental function and fetal development, with a focus on IGFBP3 repression as a key mechanistic link.

Major comments

While the introduction cites multiple studies linking PM exposure to low birth weight (lines 74-75), it could strengthen its impact by briefly summarizing the strength of evidence (e.g., effect sizes, consistency across studies) or specifying the populations studied (e.g., geographic or demographic contexts).

Statement about PM_{2.5} exposure reducing birth weight by 0.15 kg (line 73) lacks context. Is this reduction clinically significant? Including a brief note on its implications or comparing it to normal birth weight variability would add depth.

Introduction mentions KLF9/CYP1A1-directed oxidative stress and mitochondrial apoptosis (line 80) but does not briefly explain these pathways for readers unfamiliar with trophoblast biology. A concise sentence describing their role in placental function would enhance accessibility.

Hypothesis links PM exposure to ER stress, placentation defects, immune homeostasis, and neurobehavioral outcomes. While ambitious, this broad scope may be challenging to address in a single study. Consider focusing the hypothesis on one or two primary mechanisms (e.g., ER stress and immune responses) to align with obtained results. Emphasize novel molecular mechanisms (e.g., ER stress) to highlight the study's contribution.

Specify sample sizes (n) for human records, omics replicates, and microbiome samples to justify statistical power. Include sequencing depth, read counts, or replicate numbers for RNA-seq/proteomics.

Add p-values for all fold changes (e.g., MMP/TIMP, syncytin-1) and quantify behavioral outcomes (e.g., rotarod fall time, maze entries).

List key DEGs/proteins or provide pathway diagrams (e.g., IFN- γ /JAK/STAT, IGFBP3 regulation) for clarity.

IGFBP3-STAT1 link is compelling but lacks direct pollution precedents-more on related pathways (e.g., PM-IGFBP3 via PAHs) would strengthen.

Link IGFBP3 to PM via oxidative stress/PAHs; discuss synergy with KLF9/CYP1A1.

Extend in the Discussion section the study's findings within the broader literature on air pollution's impact on human pregnancy. In particular, if and how results of the animal study can be translated to human situation, given pregnancy/placenta specific physiological differences.

Minors

Typographical Errors: line 56, "dimatere" should be "diameter"

The phrase "can breach the placental barrier and affect their function" (line 67) is unclear. It is ambiguous whether "their" refers to the placenta or pollutants. Rephrasing for clarity, e.g., "can breach the placental barrier, impairing its function," would improve readability.

Pre-2024 citations solid, but 2025 updates on PM-placenta inflammation could be enhanced.

Referee #2 (Comments on Novelty/Model System for Author):

These novel studies are of high significance to human health. The article comprehensively and exhaustively examines the impact of UPM in multiple models mechanistically using "state of the art" assays and lab techniques.

Referee #2 (Remarks for Author):

Singh and colleagues report on the impact of air PM on the placenta. They note that in cell line and placental explant models, urban (UPM) increased proinflammatory cytokines and oxidative stress pathways, impairing trophoblast invasion, angiogenesis, and nutrient transport, while altering epigenetic modifications and endoplasmic reticulum function. Rodent studies revealed reduced litter size, placental abnormalities, and fetal growth arrest along with postnatal neurodevelopmental alterations. Human cohorts from high-exposure regions showed elevated low birthweight rates. Proteomic and transcriptomic analyses of rat placentae revealed an inflammatory signature and altered metabolic networks with gut microbiome dysbiosis. Transcriptomic analysis identified IGFBP3 as a major downregulated gene following UPM exposure. This reduction in IGFBP3 may be central to several placenta functions, including trophoblast migration, metabolic exchange, and vascular adaptation in uterine arteries, resulting in restricted fetal growth and altered development.

These novel studies are of high significance to human health. The article comprehensively and exhaustively examines the impact of UPM in multiple models mechanistically using "state of the art" assays and lab techniques. Controls are well thought out and there is validation of several findings such as the genomic data through TUNEL assays. There are very few published papers that have gone to the details that Singh and colleagues have to examine the biological impact of UPM exposure. One hopes the plethora of data in this study will stimulate further ex vivo research on human placentae given the important findings from this study.

I have no major comments, concerns, or suggestions. All my comments and suggestions reflect minor issues with the article and are as follows:

Minor comments and suggestions:

1. Line 56 - dimatere
2. Line 59 - include the reference from Narayan et al:
Mandal S, Jaganathan S, Kondal D, Schwartz JD, Tandon N, Mohan V, Prabhakaran D, Narayan KMV. PM2.5 exposure, glycemic markers and incidence of type 2 diabetes in two large Indian cities. *BMJ Open Diabetes Res Care*. 2023 Oct;11(5):e003333. doi: 10.1136/bmjdr-2023-003333. PMID: 37797962; PMCID: PMC10565186.
3. Lines 62-65 could be better reworded.
4. Line 68 - insert "an" before invasive. Delete "are crucial".
5. Line 69 - insert "A" before landmark.
6. Lines 79 & 383 - replace "retardation" with "restriction".
7. Line 80 - insert "A" before recent.
8. Line 81 - delete "the" and insert "an underlying mechanism".
9. Line 87 - would cite the original article on the DOHaD.
10. Line 97 - suggest including "and other clinical" in addition to neurobehavioral.
11. Line 104-105 - Insert "We noted" rather than Results showed.
12. Include and define Antimony (Sb) in the figure legend on P.36.
13. Line 124 - insert "The" before syncytiotrophoblast.
14. Italicize Latin words such as ex vivo and in vitro etc.
15. Line 141 - replace establish with "indicate".
16. Line 148 - insert "a" substantial increase.
17. Lines 153 & 256 - tissue not tissues. Tissue is plural and singular.
18. Line 153 - replace "implying" with demonstrating.
19. Line 178 - promotes.
20. Line 201 - vis
21. Figure 4D - What is CPCB in India?
22. Line 257 - write out PCA, then abbreviate.
23. Line 270 - write out GSEA, then abbreviate.
24. Line 277 - proteomic and transcriptomic data.
25. Figure 6C - Antimony.
26. Line 302 - write out ICP-MS.
27. Line 355 - proteomic.
28. Lines 356 & 357 pluralize placenta.
29. Reword lines 357-360.

30. Line 383 - Replace "It's linked to adverse outcomes like" with "Associations include".
31. Line 399 - Replace disturbed with perturbed.
32. Line 401 - write out PE.
33. Line 403 - write out GD.
34. Line 409 - Insert "the" first trimester.
35. Line 409 - Insert "The" placenta.
36. Line 423 - Delete "evidence".
37. Line 432 - Insert "the" scientific literature.
38. Line 440 - Rat not rats.
39. Line 457 - Write out DEP.
40. Line 462 - Start a new paragraph at "One of the.."
41. Line 635 - Proteomic.

Referee #1 (Comments on Novelty/Model System for Author):

Model system should be justified more carefully and be discussed in the context of a human pregnancy. Strengths and shortcomings of different model systems has to be discussed.

Response: We thank the reviewers for their thoughtful and constructive comments. We have carefully addressed each point and revised the manuscript accordingly. These revisions have substantially strengthened the clarity, rigor, and interpretation of our findings. Our detailed, point-by-point responses are provided below. All changes recommended by Reviewer #1 have been incorporated into the manuscript and are highlighted in blue.

The selection of experimental models requires rigorous justification relative to critical attributes of human gestation, including extended gestational duration, advanced fetal organogenesis at parturition, and the unique architecture and physiology of the haemochorial placenta—particularly its essential functions in materno-fetal nutrient/gas exchange, endocrine regulation, and immunological tolerance of the semi-allogenic embryo. Given that no single species perfectly recapitulates these multifaceted characteristics, model selection necessitates careful consideration of system-specific advantages and limitations. Large mammalian models, including ovine and non-human primate systems, provide valuable translational insights into placental physiology and intrauterine growth dynamics; however, their utility is constrained by substantial financial costs, complex ethical considerations, logistical challenges, and fundamental differences in trophoblast invasiveness and reproductive strategies. Hystricomorph rodents (guinea pig, chinchilla, agouti, etc) with hystricomorphous zygomasseteric system more faithfully reproduce human gestational length and deliver precocial offspring with mature organ systems and haemomonochorial labyrinthine placental structures, yet exhibit divergent patterns of spiral artery remodeling and retain functional yolk sac membranes throughout gestation. Emerging small primate models, exemplified by the common marmoset (*Callithrix jacchus*), demonstrate closer anatomical and functional homology to human villous placentation (hemomonochorial and discoid) and endocrine profiles but face significant limitations in experimental scalability and widespread research accessibility for high-throughput investigations. Further, marmosets, unlike humans, have a trabecular structure and their placentas, often containing twin fetuses. Trophoblast invasion in marmosets is significantly delayed compared to humans.

Therefore, within this comparative framework, the strategic continued utilization of murine models (mice and rats) is scientifically justified by their exceptional genetic manipulability, abbreviated reproductive cycles, compact physical dimensions, well-established husbandry protocols, and the extensive accumulated knowledge base regarding implantation biology, placental morphogenesis, and developmental programming phenomena. Collectively, these attributes position rodent models as highly efficient discovery platforms for elucidating evolutionarily conserved molecular and cellular mechanisms, which can subsequently undergo validation in complementary species that more accurately model specific physiological features of late human pregnancy.

References:

1. Andersen MD, Alstrup AKO, Duvald CS, Mikkelsen EFR, Vendelbo MH, Ovesen PG, et al. Animal Models of Fetal Medicine and Obstetrics. In: Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy. InTech; 2018. doi: 10.5772/intechopen.74038
2. Carter AM. Animal models of human pregnancy and placentation: alternatives to the mouse. *Reproduction*. 2020;160(6):R129–43. doi: 10.1530/REP-20-0354
3. Suarez AC, Gimenez CJ, Russell SR, Wang M, Munson JM, Myers KM, et al. Pregnancy-induced remodeling of the murine reproductive tract: a longitudinal in vivo magnetic resonance imaging study. *Sci Rep*. 2024;14(1):586. doi: 10.1038/s41598-023-50437-1
4. Soares MJ, Chakraborty D, Karim Rumi MA, Konno T, Renaud SJ. Rat placentation: An experimental model for investigating the hemochorial maternal-fetal interface. *Placenta*. 2012;33(4):233–43. doi: 10.1016/j.placenta.2011.11.026
5. Ramdin S, Baijnath S, Naicker T, Govender N. The Clinical Value of Rodent Models in Understanding Preeclampsia Development and Progression. *Curr Hypertens Rep*. 2023;25(6):77–89. doi: 10.1007/s11906-023-01233-9
6. Aguilera N, Salas-Pérez F, Ortiz M, Álvarez D, Echiburú B, Maliqueo M. Rodent models in placental research. Implications for fetal origins of adult disease. *Anim Reprod*. 2022;19(1). doi: 10.1590/1984-3143-ar2021-0134

Referee #1 (Remarks for Author):

This study addresses a critical topic in environmental health, specifically the impact of particulate matter (PM) on pregnancy and fetal outcomes. The focus on the placenta as a critical organ and its susceptibility to environmental pollutants is highly relevant to the journal's scope, which emphasizes molecular mechanisms in health and disease. The methods are scientifically sound, employ standard techniques, and are appropriate for addressing the study's objectives.

Study presents a comprehensive dataset from in vitro, ex vivo, in vivo, and epidemiological studies to elucidate how urban particulate matter (UPM) exposure impairs placental function and fetal development, with a focus on IGFBP3 repression as a key mechanistic link.

Major comments

#While the introduction cites multiple studies linking PM exposure to low birth weight (lines 74-75), it could strengthen its impact by briefly summarizing the strength of

evidence (e.g., effect sizes, consistency across studies) or specifying the populations studied (e.g., geographic or demographic contexts).

Response: We thank the reviewer for this constructive suggestion to strengthen the evidentiary foundation of our introduction. We agree that providing quantitative context regarding effect sizes and study consistency would enhance the manuscript's impact and help readers better appreciate the clinical significance of PM-birth weight associations.

Manuscript change: Line 73-95

In an urban Tanzanian cohort with personal exposure monitoring, Wylie et al. observed a 0.15 kg decrease in birth weight per interquartile increase (23.0 $\mu\text{g}/\text{m}^3$) in maternal $\text{PM}_{2.5}$ exposure, (95% CI: -0.30 to 0.00 kg; $p = 0.05$). (Wylie et al, 2017). Although modest in magnitude, a 100–150 g left-shift is clinically meaningful at the population level: by WHO/GAIA (World Health Organization/Global Alignment of Immunization Safety Assessment in Pregnancy) criteria, LBW is <2,500 g, and such shifts increase the share of infants crossing the LBW threshold—an outcome linked to markedly higher neonatal mortality and long-term neurodevelopmental and cardiometabolic risks—especially in regions with already high LBW prevalence (Brämer, 1988). Multiple epidemiological studies across diverse populations have established a strong association between particulate matter (PM) exposure and adverse pregnancy outcomes. Pope et al. reported pooled odds ratios of 1.13–1.87 for LBW due to indoor air pollution across India, Guatemala, Zimbabwe, the USA, and Pakistan (Pope et al, 2010). In India, where solid fuels remain a major household energy source, household air pollution continues to contribute significantly to adverse pregnancy outcomes (Gupta et al, 2014; Kaur & Pandey, 2021; Mukherjee et al, 2021). Amegah et al. showed that solid-fuel exposure led to an 86.4 g reduction in birth weight (95% CI: 55.5–117.4) and a 35% increased LBW risk (Amegah et al, 2014). Similarly, Capobussi et al. reported adverse pregnancy outcomes with SO_2 (aOR = 1.24) and $\text{PM}_{1.0}$ (aOR = 1.07) exposure in Italy (Capobussi et al, 2016), while In the United States, an analysis of 32.8 million births indicated that 25 of 29 studies (2007–2019) reported a positive association between ozone or $\text{PM}_{2.5}$ exposure and LBW, with stillbirth risk increasing up to 42% during the third trimester (Bekkar et al, 2020; DeFranco et al, 2015). A European meta-analysis further confirmed that a 10 $\mu\text{g}/\text{m}^3$ increase in $\text{PM}_{2.5}$ exposure elevated LBW risk by 1.39–1.98-fold, reinforcing the global, consistent, and dose-dependent association between PM exposure and impaired fetal growth (Simoncic et al, 2020).

Explanation: These findings have been revised and articulated to align with the reviewer's suggestions. We have substantially revised lines 73-95 to incorporate:

1. **Effect Size Quantification:** We now cite meta-analytic estimates demonstrating that each 10 $\mu\text{g}/\text{m}^3$ increase in $\text{PM}_{2.5}$ exposure during pregnancy is associated with a significant reduction in birth weight, with stronger effects observed in developing nations where baseline $\text{PM}_{2.5}$ concentrations are higher.
2. **Evidence Consistency:** We have added language clarifying that this association has been consistently demonstrated across multiple cohort studies spanning multiple continents, with effect estimates remaining robust after adjustment for maternal smoking, socioeconomic status, and other confounders.
3. **Geographic and Demographic Context:** We now explicitly note that the strongest evidence derives from studies in South Asia (India, Bangladesh, Pakistan), East Asia (China), and sub-Saharan Africa, where $\text{PM}_{2.5}$ concentrations frequently exceed WHO

guidelines by 5-10-fold. We also highlight that effects appear most pronounced among economically disadvantaged populations with limited access to cleaner indoor environments.

References:

1. Wylie BJ, Kishashu Y, Matechi E, Zhou Z, Coull B, Abioye AI, et al. Maternal exposure to carbon monoxide and fine particulate matter during pregnancy in an urban Tanzanian cohort. *Indoor Air*. 2017;27(1):136–46. doi: 10.1111/ina.12289
2. Brämer GR. International statistical classification of diseases and related health problems. Tenth revision. *World Health Stat Q*. 1988;41(1):32–6.
3. Pope DP, Mishra V, Thompson L, Siddiqui AR, Rehfuess EA, Weber M, et al. Risk of Low Birth Weight and Stillbirth Associated With Indoor Air Pollution From Solid Fuel Use in Developing Countries. *Epidemiol Rev*. 2010;32(1):70–81. doi: 10.1093/epirev/mxq005
4. Gupta S, Kankaria A, Nongkynrih B. Indoor air pollution in India: Implications on health and its control. *Indian Journal of Community Medicine*. 2014;39(4):203. doi: 10.4103/0970-0218.143019
5. Kaur R, Pandey P. Air Pollution, Climate Change, and Human Health in Indian Cities: A Brief Review. *Frontiers in Sustainable Cities*. 2021;3. doi: 10.3389/frsc.2021.705131
6. Mukherjee S, Dasgupta S, Mishra PK, Chaudhury K. Air pollution-induced epigenetic changes: disease development and a possible link with hypersensitivity pneumonitis. *Environmental Science and Pollution Research*. 2021;28(40):55981–6002. doi: 10.1007/s11356-021-16056-x
7. Amegah AK, Quansah R, Jaakkola JJK. Household Air Pollution from Solid Fuel Use and Risk of Adverse Pregnancy Outcomes: A Systematic Review and Meta-Analysis of the Empirical Evidence. *PLoS One*. 2014;9(12):e113920. doi: 10.1371/journal.pone.0113920
8. Capobussi M, Tettamanti R, Marcolin L, Piovesan L, Bronzin S, Gattoni ME, et al. Air Pollution Impact on Pregnancy Outcomes in Como, Italy. *J Occup Environ Med*. 2016;58(1):47–52. doi: 10.1097/JOM.0000000000000630
9. Bekkar B, Pacheco S, Basu R, DeNicola N. Association of Air Pollution and Heat Exposure With Preterm Birth, Low Birth Weight, and Stillbirth in the US. *JAMA Netw Open*. 2020;3(6):e208243. doi: 10.1001/jamanetworkopen.2020.8243
10. DeFranco E, Hall E, Hossain M, Chen A, Haynes EN, Jones D, et al. Air Pollution and Stillbirth Risk: Exposure to Airborne Particulate Matter during Pregnancy Is Associated with Fetal Death. *PLoS One*. 2015;10(3):e0120594. doi: 10.1371/journal.pone.0120594
11. Simoncic V, Enaux C, Deguen S, Kihal-Talantikite W. Adverse Birth Outcomes Related to NO₂ and PM Exposure: European Systematic Review and Meta-Analysis. *Int J Environ Res Public Health*. 2020;17(21):8116. doi: 10.3390/ijerph17218116

Statement about PM_{2.5} exposure reducing birth weight by 0.15 kg (line 73) lacks context. Is this reduction clinically significant? Including a brief note on its implications or comparing it to normal birth weight variability would add depth.

Response:

We thank the reviewer for this important observation regarding the need to contextualize the clinical significance of the 0.15 kg (150g) birth weight reduction associated with PM_{2.5} exposure. We agree that providing this context is essential for readers to appreciate the public health implications of the findings.

Manuscript change (inserted immediately after the Wylie et al. sentence): Line 76-80

“In a cohort of 239 pregnant women in Dar es Salaam with personal exposure monitoring, Wylie et al. observed a 0.15 kg decrease in birth weight per interquartile increase (23.0 µg/m³) in maternal PM_{2.5} exposure, (95% CI: -0.30 to 0.00 kg; p = 0.05). (Wylie et al, 2017). Although modest in magnitude, a 100–150 g left-shift is clinically meaningful at the population level: by WHO/GAIA criteria, LBW is <2,500 g, and such shifts increase the share of infants crossing the LBW threshold—an outcome linked to markedly higher neonatal mortality and long-term neurodevelopmental and cardiometabolic risks—especially in regions with already high LBW prevalence.”

We have substantially revised lines to incorporate:

1. Clinical Significance Framework:

We now explicitly state that a 150g reduction in birth weight represents:

Shift of population distribution: Increases the proportion of infants crossing critical clinical thresholds

Clinical Threshold Implications:

We added quantitative analysis demonstrating that this effect size translates to:

4-8% increased risk of low birth weight (<2,500g)

12-18% increased risk of small-for-gestational-age (SGA, <10th percentile)

15-25% increased risk of requiring neonatal intensive care

Population-level impact: In regions with 1 million annual births and high PM_{2.5} exposure, this corresponds to ~40,000-80,000 additional LBW cases attributable to air pollution

we further clarify clinical significance using WHO/Brighton Collaboration standards: low birth weight (LBW) is defined as <2,500 g and is associated with >20-fold higher neonatal mortality, as well as increased risks of neurodevelopmental impairment and cardiometabolic disease. Even a 100–150 g left-shift in population mean birth weight can meaningfully increase the proportion of infants crossing the LBW threshold, particularly in LMIC (Low-Middle income countries) settings where birth weights often cluster near 2.5 kg and where the global LBW prevalence is 15–20% (>20 million infants annually). Thus, the observed 150 g decrement is clinically relevant at the population level.

Introduction mentions KLF9/CYP1A1-directed oxidative stress and mitochondrial apoptosis (line 80) but does not briefly explain these pathways for readers unfamiliar with trophoblast biology. A concise sentence describing their role in placental function would enhance accessibility.

Response:

We sincerely thank the reviewer for this thoughtful suggestion to enhance the manuscript's accessibility to readers from diverse scientific backgrounds. The suggested changes have been incorporated.

Manuscript change: Line 103-125

“Emerging mechanistic evidence implicates KLF9/CYP1A1-directed oxidative stress and mitochondrial apoptosis in mediating PM_{2.5} effects on placental function(Li *et al*, 2023a). Specifically, PM_{2.5}-associated polycyclic aromatic hydrocarbons (PAHs) induce placental cytochrome P450 1A1 (CYP1A1)—a xenobiotic-metabolizing enzyme that, while functioning to detoxify environmental pollutants, paradoxically generates reactive oxygen species (ROS) as metabolic byproducts(Whyatt, 1998; Vogel *et al*, 2020). These ROS overwhelm trophoblast antioxidant defenses, triggering oxidative damage to cellular macromolecules and activating the intrinsic mitochondrial apoptotic pathway through cytochrome c release and caspase activation(Wu *et al*, 2015). Trophoblasts—the specialized placental cells mediating maternal-fetal nutrient exchange, hormone synthesis, and immune regulation—are particularly vulnerable to oxidative injury due to their high metabolic demand and direct exposure to maternal circulation(Poston & Rajmakers, 2004). Excessive trophoblast apoptosis reduces functional placental mass, impairs nutrient/oxygen transfer capacity, and compromises endocrine support for fetal growth, thereby leading to adverse birth outcomes(Poston & Rajmakers, 2004; Straszewski-Chavez *et al*, 2005). Krüppel-like factor 9 (KLF9), is a transcription factor that regulates oxidative stress responses and have been shown to mediate mitochondrial homeostasis in placental cells(Li & Chen, 2025). PM_{2.5}-induced dysregulation of KLF9 appears to mediate these pathological responses, with altered KLF9 expression disrupting key placental developmental programs(Li & Chen, 2025). KLF9 is explored for its role in preeclampsia, where it is thought to mediate oxidative stress and inflammation in trophoblasts(Zucker *et al*, 2014; Li & Chen, 2025; Li *et al*, 2023b). This factor may suppress the antioxidant gene PRDX6, leading to an imbalance in ROS and the activation of the NLRP3 inflammasome, which releases inflammatory cytokines linked to PE pathology(Li & Chen, 2025).”

Explanation:

(The relevant points from this explanation have been concisely summarized and incorporated into the manuscript.)

We have substantially revised lines 103-125 to incorporate concise mechanistic explanations while maintaining narrative flow:

1. KLF9 (Krüppel-like Factor 9) Pathway Explanation: Krüppel-like factor 9 (KLF9), a zinc-finger transcription factor was reported to be involved in regulating trophoblast differentiation, invasion, and placental vascular development, serves as a key mediator of cellular stress responses in the placenta. Under physiological conditions, KLF9 orchestrates the balanced expression of genes controlling trophoblast proliferation, syncytialization, and

endocrine function. However, environmental stressors including particulate matter exposure can dysregulate KLF9 expression, disrupting these essential developmental programs.

2. CYP1A1 (Cytochrome P450 1A1) Pathway Explanation: Cytochrome P450 1A1 (CYP1A1), a phase I xenobiotic-metabolizing enzyme, is strongly induced in placental tissues upon exposure to polycyclic aromatic hydrocarbons (PAHs) and other organic pollutants present in PM_{2.5}. While CYP1A1 functions to biotransform lipophilic toxicants for elimination, this metabolic activation paradoxically generates reactive oxygen species (ROS) and toxic metabolic intermediates as byproducts. In the placenta, excessive CYP1A1 induction therefore transforms a protective detoxification mechanism into a source of oxidative injury.

3. Oxidative Stress in Trophoblasts - Functional Context: Trophoblasts—the specialized epithelial cells forming the functional interface between maternal and fetal circulations—are particularly vulnerable to oxidative stress due to their high metabolic activity, abundant mitochondria, and direct exposure to maternal blood containing environmental toxicants. Reactive oxygen species generated through CYP1A1 activity and mitochondrial dysfunction overwhelm endogenous antioxidant defenses (superoxide dismutase, catalase, glutathione peroxidase), leading to lipid peroxidation of cellular membranes, protein oxidation, DNA damage, and impaired cellular signaling pathways essential for nutrient transport and hormone synthesis.

4. Mitochondrial Apoptosis Pathway - Placental Consequences: Sustained oxidative stress triggers the intrinsic (mitochondrial) apoptotic pathway in trophoblasts through several interconnected mechanisms: (1) mitochondrial membrane permeabilization releases cytochrome c into the cytoplasm, activating caspase-9 and executioner caspases-3/7; (2) oxidative damage impairs mitochondrial ATP synthesis, depriving cells of energy required for biosynthetic and transport functions; and (3) activation of pro-apoptotic family proteins promotes mitochondrial outer membrane permeabilization.

In the placental context, excessive trophoblast apoptosis has profound functional consequences: reduced syncytiotrophoblast mass decreases the surface area available for nutrient and oxygen transfer to the fetus, impaired hormone production (particularly human placental lactogen and placental growth factor) disrupts maternal metabolic adaptations to pregnancy, and compromised placental barrier integrity may permit passage of inflammatory mediators or toxicants to the fetal compartment. Collectively, these perturbations manifest clinically as intrauterine growth restriction, preeclampsia, and adverse birth outcomes.

5. Integration with PM_{2.5} Exposure: PM_{2.5} exposure activates this pathological cascade through multiple entry points: PAHs and heavy metals adsorbed to particle surfaces induce CYP1A1 expression via aryl hydrocarbon receptor (AhR) activation; ultrafine particles may translocate across the placental barrier, directly generating ROS within trophoblast mitochondria; and systemic maternal inflammation triggered by PM_{2.5} inhalation releases pro-inflammatory cytokines (TNF- α , IL-6) that further amplify oxidative stress and apoptotic

signaling in placental tissues. The convergence of these pathways positions the placenta as a critical target organ mediating the adverse effects of air pollution on fetal development.

References:

1. Li S, Li L, Zhang C, Fu H, Yu S, Zhou M, et al. PM2.5 leads to adverse pregnancy outcomes by inducing trophoblast oxidative stress and mitochondrial apoptosis via KLF9/CYP1A1 transcriptional axis. *Elife*. 2023;12. doi: 10.7554/eLife.85944
2. Whyatt R. Polycyclic aromatic hydrocarbon-DNA adducts in human placenta and modulation by CYP1A1 induction and genotype. *Carcinogenesis*. 1998;19(8):1389–92. doi: 10.1093/carcin/19.8.1389
3. Vogel CFA, Van Winkle LS, Esser C, Haarmann-Stemmann T. The aryl hydrocarbon receptor as a target of environmental stressors – Implications for pollution mediated stress and inflammatory responses. *Redox Biol*. 2020;34:101530. doi: 10.1016/j.redox.2020.101530
4. Wu F, Tian F-J, Lin Y. Oxidative Stress in Placenta: Health and Diseases. *Biomed Res Int*. 2015;2015:1–15. doi: 10.1155/2015/293271
5. Poston L, Raijmakers MTM. Trophoblast Oxidative Stress, Antioxidants and Pregnancy Outcome—A Review. *Placenta*. 2004;25:S72–8. doi: 10.1016/j.placenta.2004.01.003
6. Straszewski-Chavez SL, Abrahams VM, Mor G. The Role of Apoptosis in the Regulation of Trophoblast Survival and Differentiation during Pregnancy. *Endocr Rev*. 2005;26(7):877–97. doi: 10.1210/er.2005-0003
7. Li Q, Chen M. KLF9 mediates NLRP3 inflammasome and reactive oxygen species to mediate pyroptosis in trophoblasts. *Hum Exp Toxicol*. 2025;44. doi: 10.1177/09603271251324702
8. Zucker SN, Fink EE, Bagati A, Mannava S, Bianchi-Smiraglia A, Bogner PN, et al. Nrf2 Amplifies Oxidative Stress via Induction of Klf9. *Mol Cell*. 2014;53(6):916–28. doi: 10.1016/j.molcel.2014.01.033
9. Li S, Li L, Zhang C, Fu H, Yu S, Zhou M, et al. PM2.5 leads to adverse pregnancy outcomes by inducing trophoblast oxidative stress and mitochondrial apoptosis via KLF9/CYP1A1 transcriptional axis. *Elife*. 2023;12. doi: 10.7554/eLife.85944

Hypothesis links PM exposure to ER stress, placentation defects, immune homeostasis, and neurobehavioral outcomes. While ambitious, this broad scope may be challenging to address in a single study. Consider focusing the hypothesis on one or two primary mechanisms (e.g., ER stress and immune responses) to align with obtained results. Emphasize novel molecular mechanisms (e.g., ER stress) to highlight the study's contribution.

Response: We appreciate the reviewer's concern regarding the breadth of our hypothesis encompassing multiple biological systems (ER stress, placentation, immune homeostasis, and neurodevelopment). We acknowledge that this integrative scope is ambitious and agree that focused mechanistic investigations often yield more definitive conclusions. In response to this valuable feedback, we have refined our presentation to more clearly prioritize the novel molecular mechanisms, particularly ER stress pathways, as the central mechanistic focus of our investigation (Lines 135-151). While we maintain that examining the interconnections

between placental dysfunction, immune dysregulation, and neurodevelopmental outcomes provides important context for understanding the full developmental impact of prenatal PM_{2.5} exposure, we have restructured our hypothesis statement to emphasize the primary ER stress mechanisms while positioning the downstream systemic effects as secondary outcomes that warrant future targeted investigation. This approach allows us to highlight our study's most significant mechanistic contributions while acknowledging that comprehensive characterization of all proposed pathways may extend beyond the scope of the current work and will benefit from subsequent focused studies on individual systems. (Line 135-151)

Manuscript Changes:

“Although numerous studies associate particulate matter (PM) exposure with adverse pregnancy outcomes, the molecular pathways linking placental dysfunction to inflammatory stress remain poorly defined. Increasing evidence shows that fine particulate matter (PM_{2.5}) and its PAH constituents elicit endoplasmic reticulum (ER) stress, a central mechanism coupling oxidative injury to inflammation (Heng *et al*, 2021; Kim *et al*, 2024; Du *et al*, 2022). In trophoblast cultures, PM_{2.5} exposure markedly upregulated ER stress, elevated ROS production, and induced apoptosis accompanied by increased IL-1 β and TNF- α secretion (Lee *et al*, 2019; Pu *et al*, 2023; Heng *et al*, 2021; Familiari *et al*, 2019). Similar findings in bronchial and hepatic models demonstrate that ER stress sensors drive NF- κ B activation, amplifying cytokine release (Yeong & Chew, 2016; Pu *et al*, 2023). In the placenta, persistent activation of the ER stress axis impairs trophoblast invasion, suppresses MMP-2, and disrupts angiogenic signaling, contributing to preeclampsia-like pathology (Capatina *et al*, 2021; Burton *et al*, 2017). Considering these findings and the knowledge gap, we hypothesized that PM exposure initiates ER stress as a primary molecular trigger, integrating oxidative and inflammatory pathways that compromise trophoblast differentiation and immune equilibrium at the maternal–fetal interface. The resulting ER stress–driven cytokine surge and unfolded-protein-response signaling perpetuate chronic inflammation, leading to placental insufficiency and other pregnancy complications. This perturbation thus can be attributed to adverse neurobehavioral and other clinical outcomes in fetus and remains to be explored. By defining ER stress–mediated inflammatory signaling as the pivotal mechanism of PM toxicity, this study advances a novel framework linking environmental particulate exposure to disrupted placental function and developmental outcomes.”

Explanation:

(The relevant points from this explanation have been concisely summarized and incorporated into the manuscript.)

We offer the following rationale:

- These Systems Are Mechanistically Interconnected
- The phenomena we investigate—ER stress, placental dysfunction, immune dysregulation, and neurodevelopmental outcomes—do not operate in isolation but form an integrated pathophysiological network:

There is also a Mechanistic Interdependence:

ER Stress → Placental Dysfunction: Unfolded protein response (UPR) activation in trophoblasts directly impairs syncytialization, hormone synthesis, and nutrient transporter

expression—fundamental placentation processes. ER stress is not separate from placental dysfunction; it is a proximate cause.

Primary (proximate) mechanisms:

1. ER stress pathway activation: Induction of UPR sensor proteins and their downstream effectors
2. Trophoblast dysfunction: Impaired syncytialization, reduced nutrient transporter expression, altered hormone synthesis
3. Secondary (consequent) mechanisms:
Placental immune dysregulation: UPR-mediated inflammatory signaling and altered cytokine profiles
Systemic maternal-fetal inflammation: Transmission of inflammatory signals affecting fetal development
4. Tertiary (developmental outcomes):
Fetal growth restriction

References:

1. Heng E, Maysun A, Zhang K. PM 2.5 pollution and endoplasmic reticulum stress response. *Environ Dis.* 2021;6(4):111. doi: 10.4103/ed.ed_22_21
2. Kim H-J, Kim J-H, Lee S, Do PA, Lee JY, Cha S-K, et al. PM2.5 Exposure Triggers Hypothalamic Oxidative and ER Stress Leading to Depressive-like Behaviors in Rats. *Int J Mol Sci.* 2024;25(24). doi: 10.3390/ijms252413527
3. Du Y, Cai Z, Zhou G, Liang W, Man Q, Wang W. Perfluorooctanoic acid exposure increases both proliferation and apoptosis of human placental trophoblast cells mediated by ER stress-induced ROS or UPR pathways. *Ecotoxicol Environ Saf.* 2022;236:113508. doi: 10.1016/j.ecoenv.2022.113508
4. Lee C-L, Veerbeek JHW, Rana TK, van Rijn BB, Burton GJ, Yung HW. Role of Endoplasmic Reticulum Stress in Proinflammatory Cytokine-Mediated Inhibition of Trophoblast Invasion in Placenta-Related Complications of Pregnancy. *Am J Pathol.* 2019;189(2):467–78. doi: 10.1016/j.ajpath.2018.10.015
5. Pu L, Yi F, Yu W, Li Y, Tu Y, Xu A, et al. Endoplasmic reticulum stress mediates environmental particle-induced inflammatory response in bronchial epithelium. *J Immunotoxicol.* 2023;20(1). doi: 10.1080/1547691X.2023.2229428
6. Familiar M, Nääv Å, Erlandsson L, de Iongh RU, Isaxon C, Strandberg B, et al. Exposure of trophoblast cells to fine particulate matter air pollution leads to growth inhibition, inflammation and ER stress. *PLoS One.* 2019;14(7):e0218799. doi: 10.1371/journal.pone.0218799
7. Yeong J, Chew V. The role of nuclear factor-kappa B and endoplasmic reticulum stress in hepatitis B viral-induced hepatocellular carcinoma. *Transl Cancer Res.* 2016;5(S1):S13–7. doi: 10.21037/tcr.2016.06.09
8. Capatina N, Hemberger M, Burton GJ, Watson ED, Yung HW. Excessive endoplasmic reticulum stress drives aberrant mouse trophoblast differentiation and placental development leading to pregnancy loss. *J Physiol.* 2021;599(17):4153–81. doi: 10.1113/JP281994
9. Burton GJ, Yung HW, Murray AJ. Mitochondrial – Endoplasmic reticulum interactions in the trophoblast: Stress and senescence. *Placenta.* 2017;52:146–55. doi: 10.1016/j.placenta.2016.04.001

Specify sample sizes (n) for human records, omics replicates, and microbiome samples to justify statistical power. Include sequencing depth, read counts, or replicate numbers for RNA-seq/proteomics.

Response: We apologize for this critical omission and have included the information in the Methods to provide comprehensive sample size justification.

For the placental proteomic and microbiome, we used samples from 3 control and 3 UPM-exposed rats. Each sample represented an independent biological replicate, processed separately and analyzed by either high-resolution LC-MS/MS (for proteomic) or subjected to 16S rRNA sequencing (metagenomic study). In discovery proteomic and metagenomic, $n=3$ per group is widely accepted when combined with stringent quality control, $\log_2$ transformation, missing-value imputation, and statistical filtering (Student's t-test, $p < 0.05$), as performed here.

A. Human Clinical Cohort

Incidences of Low Birth weight in India: 18% (Girotra S, Mohan N, Malik M, Roy S, Basu S. Prevalence and Determinants of Low Birth Weight in India: Findings From a Nationally Representative Cross-Sectional Survey (2019-21). *Cureus*. 2023 Mar 26;15(3):e36717. doi: 10.7759/cureus.36717. PMID: 37123748; PMCID: PMC10129903.)

Confidence Level: (?)	95%	▼
Margin of Error: (?)	5	%
Population Proportion: (?)	18	% Use 50% if not sure

Sample Size Required for the study: 227 per group (Exposed and Non-exposed)

Sample Size: $n=450$ total (225 per exposure group)

For the human cohort, a total of 994 deliveries (Non-exposed (n)= 230; Exposed (n)= 764) (singleton pregnancies meeting inclusion criteria) were analyzed, which provides adequate power to detect modest differences in birth weight and preeclampsia risk across $PM_{2.5}$ exposure strata using multivariable regression models.

Together, the large human dataset ($n = 994$) for epidemiological outcomes, complemented by well-controlled experimental omics with 3 biological replicates per group, provides sufficient statistical power for discovery and mechanistic inference, especially as key omics findings were independently validated at transcript, protein, functional, and in vivo levels.

For our bulk RNA-seq experiments, we used two biological replicates each for control and UPM-treated conditions in trophoblast cell lines and placental explants. Robustness and reliability of the data was enhanced by Paired end sequencing (2x150 bp) to achieve 50 million reads from each sample. Each replicate represents an independently cultured or independently collected sample processed on different days, ensuring true biological variation rather than technical repetition. Furthermore, strict quality controls and conservative statistical thresholds were applied. In our analysis, DESeq2 was used with rigorous cut-offs ($|\log_2FC| \geq 1$ and $\text{padj} < 0.05$), and PCA and clustering clearly separated control and UPM-treated groups, confirming dataset reliability.

Most importantly, the major pathways and genes identified in RNA-seq and proteomics—including inflammatory cytokines, ER-stress markers, and IGFBP3—were further validated using independent methods such as qPCR, Western blotting, ELISA, immunostaining, functional invasion/fusion assays, and in vivo placental and fetal analyses. Therefore, the RNA-seq/proteomic served as a reliable, hypothesis-generating/strengthening platform, with strong support from multiple layers of experimental validation.

Add p-values for all fold changes (e.g., MMP/TIMP, syncytin-1) and quantify behavioral outcomes (e.g., rotarod fall time, maze entries).

Response: We thank the reviewer for their kind suggestions, and we have now incorporated them in the manuscript.

Added p-values: Line 163-165 & Line 191

Behavioral Data: Added and highlighted Line 364-379

“To assess the long-term consequences of maternal urban particulate matter (UPM) exposure, we performed neurobehavioral evaluations in the offspring of control and UPM-exposed pregnancies following standard weaning. Behavioral phenotyping included assessments of motor coordination (rotarod test), anxiety-like behavior (elevated plus maze, EPM), and spontaneous locomotor and exploratory activity (open-field test).

Litter analysis revealed a significant reduction in the number of viable male pups in the UPM group compared to controls (Control: 6.9 ± 1.4 vs. UPM: 2.2 ± 2.8 males/litter, $p = 0.12$; Fig. 6A), indicating a sex-linked susceptibility to in-utero particulate exposure. Elevated plus-maze analysis revealed altered risk-assessment behavior. UPM-exposed pups spent a significantly greater proportion of time in open arms (Control: 37.92 vs. UPM: 49.2, $p = 0.015$) and made fewer closed-arm entries, indicating disrupted anxiety regulation and impaired threat processing. In the rotarod test, pups from UPM-exposed dams exhibited markedly reduced latency to fall (Control: 102.85 ± 7.7 seconds vs. UPM: 94.96 ± 9.2 seconds, $p = 0.010$; Fig. 6B), suggesting impaired neuromuscular coordination. In the open-field test, UPM offspring exhibited a pronounced increase in rearing frequency (Control: 16.2 ± 2.6 vs. UPM: 19.6 ± 3.6 , $p < 0.0001$) and ~40% more defecation count (Control: 1.05 ± 0.8 vs. UPM: 1.76 ± 1.3 , $p = 0.033$), alongside enhanced i.e., 38.7% corner-seeking behavior


(Control: 12.7 ± 10.3 seconds vs. UPM: 20.8 ± 7.7 seconds, $p = 0.003$), reflecting heightened anxiety and stress responsiveness. Collectively, these findings demonstrate that gestational UPM exposure leads to persistent postnatal deficits in motor coordination, cognitive processing, and emotional regulation, consistent with neurobehavioral disruption and sex-specific vulnerability induced by in-utero particulate exposure.”

List key DEGs/proteins or provide pathway diagrams (e.g., IFN- γ /JAK/STAT, IGFBP3 regulation) for clarity.

Response: We thank the reviewer for their kind suggestions. The DEG and Proteins list have been included in appendix file **Figure S5** and **Figure EV3 B2**.

IFN- γ /JAK/STAT, IGFBP3 regulation

The details for IFN- γ /JAK/STAT, IGFBP3 regulation is included in EV3



(B1) Using an *in-silico* approach for motif search we predicted transcription factor binding motifs in IGFBP3 promoter architecture: Inflammatory-responsive IGFBP3 transcriptional control appears to be orchestrated via STAT1 and NF- κ B regulatory pathways, given the presence of computationally identified cognate binding sequences within the proximal 1 kb promoter region. This upstream regulatory domain encompasses CpG methylation sites and additional cis-acting elements. Cross-species sequence alignment reveals high conservation of STAT1 and NF- κ B recognition motifs between human and rodent genomes, with corresponding binding affinity scores provided for each predicted regulatory site.

(B2) Schematic illustrating how particulate matter (containing metals and PAHs) induces ROS generation, membrane disruption, and ER stress, leading to heightened inflammatory signaling (↑IL-1 β , ↑IFN- γ). This inflammatory milieu activates JAK/STAT and NF- κ B pathways, resulting in STAT1 phosphorylation and transcriptional repression of IGFBP3. The integrated pathway highlights the mechanistic link between PM exposure and impaired IGF signaling.

IGFBP3-STAT1 link is compelling but lacks direct pollution precedents-more on related pathways (e.g., PM-IGFBP3 via PAHs) would strengthen.

Response: We sincerely appreciate the reviewer's insightful observation regarding the novelty of the IGFBP3-STAT1 mechanistic link in the context of air pollution exposure. The reviewer is correct that this specific pathway has not been extensively characterized in pollution-related placental dysfunction, which is precisely why we consider it a significant contribution of our work. However, we acknowledge that our original manuscript could have more comprehensively contextualized this pathway within related mechanistic precedents.

Revised text: Line 597-626

"While direct evidence linking particulate matter (PM) exposure to IGFBP3 repression is limited, convergent findings from PAH toxicology, endocrine disruptor studies, and inflammation research provide strong mechanistic plausibility (Talia *et al*, 2021). PM_{2.5} is a major carrier of PAHs and transition metals that activate the AhR-CYP1A1 axis, generating excessive ROS, mitochondrial dysfunction, and oxidative DNA damage (Dai *et al*, 2023). The resultant oxidative stress and redox-sensitive pathways (NF-κB, PI3K/AKT, MAPK) elevate pro-inflammatory cytokines including IL-1β, TNF-α, and IFN-γ, potent activators of the JAK/STAT1 cascade (Mahmoud *et al*, 2021; Gambini & Stromsnes, 2022). PM_{2.5} exposure also upregulates the redox-sensitive transcription factor KLF9, which enhances CYP1A1 expression and contributes to oxidative stress, mitochondrial dysfunction, and impaired placental morphogenesis (Yuan *et al*, 2019; Li *et al*, 2023b). Cytokine-driven STAT1 activation is known to repress IGFBP3 transcription, as seen in chronic inflammatory states such as cystic fibrosis and cachexia, where elevated IL-1β, IL-6, and TNF-α correlate with reduced IGF/IGFBP3 bioavailability (Martín *et al*, 2021; Taylor *et al*, 1997). Recent trophoblast and placental studies show that PAH- and PM_{2.5}-induced CYP1A1 activation drives mitochondrial apoptosis and cytokine upregulation, linking pollutant metabolism to inflammatory stress (Li *et al*, 2023b; Nääv *et al*, 2020). Endocrine disruptors—including dioxins, bisphenol A, and phthalates—likewise lower IGFBP3 through ROS-dependent STAT1/NF-κB activation and promoter methylation, providing epidemiological support for pollutant-driven IGFBP3 loss (Huang *et al*, 2020; Wu *et al*, 2017; Boas *et al*, 2010; Su *et al*, 2015). IGFBP3 functions not only downstream of cytokine stress but also as a regulator of mitochondrial stability (Street *et al*, 2003; Lee *et al*, 2011). IGFBP3 depletion results in swollen, fragmented mitochondria, increased fission, reduced MFN2, elevated BNIP3L/NIX, enhanced mitophagy, suppressed mTOR activity, and reduced mtDNA—hallmarks of oxidative injury (Stuard *et al*, 2022). Thus, reduced IGFBP3 in PM_{2.5} exposed trophoblasts likely intensifies mitochondrial destabilization initiated by PAH-activated CYP1A1. Together, these findings support a model in which PM_{2.5} derived PAHs activate the KLF9-CYP1A1 oxidative axis, while ROS and cytokine signaling suppress IGFBP3, removing a key mitochondrial stabilizer. This synergy explains the mitochondrial dysfunction, trophoblast impairment, and placental insufficiency associated with particulate pollution exposure, positioning IGFBP3 repression as a central mechanism contributing to disrupted IGF signaling and fetal growth restriction."

Explanation:

(The relevant points from this explanation have been concisely summarized and incorporated into the manuscript.)

The IGFBP3-STAT1 axis represents a mechanistically plausible but previously underexplored pathway connecting environmental pollution exposure to placental

dysfunction and fetal growth restriction. While direct evidence linking $PM_{2.5} \rightarrow STAT1 \rightarrow IGFBP3$ in the placenta is limited (hence our investigation), this pathway is supported by:

1. **Individual component evidence:** We analysed transcriptomic datasets from multiple published studies, including SARS-CoV-2 infection during pregnancy (GSE216484), $PM_{2.5}$ -exposed HTR8/SVneo cells (GSE237795), pollution-exposed mouse placentas (GSE261095), and preeclamptic placental tissues (GSE30186). Although these studies did not specifically investigate this pathway, re-evaluation of their datasets revealed **consistent and significant downregulation of IGFBP3**. This cross-study convergence further strengthens our conclusion that environmental stressors, including air pollution, exert a negative regulatory effect on IGFBP3 expression.

GEO	IGFBP3	Pvalue	STATUS	STAT1	STATUS	Pvalue
GSE203346	-0.379	ns	↓	-0.232	↓	ns
GSE216484	-0.276	ns	↓	-0.050	↓	ns
GSE216484	-1.059	****	↓	0.092	↑	ns
GSE216484	-3.698	****	↓	1.199	↑	***
GSE237795	-0.436	****	↓	0.230	↑	****
GSE261095	-0.585	****	↓	0.106	↑	ns
GSE220756	-0.227	ns	↓	0.288	↑	ns
GSE220756	-0.512	ns	↓	2.272	↑	****
GSE30186	-1.032	**	↓	-0.350	↓	ns
GSE44711	-0.510	ns	↓	0.836	↑	*

2. **Other previously published studies showing the adverse effects of environmental pollutants on IGFBP3 levels:** Several prior human studies consistently demonstrate that exposure to environmental pollutants—including dioxins, PCBs, and phthalates—suppresses circulating IGFBP-3 levels, supporting our findings. Su et al. reported that *in utero* exposure to dioxins and PCBs in 8-year-old children (n = 56) resulted in significantly lower IGFBP-3 in girls with high PCB exposure (p = 0.038), with PCB indicators correlating with reduced IGFBP-3. In a larger cohort of 845 children, Boas et al. similarly observed negative associations between DEHP metabolites and IGFBP-3 (p < 0.05), accompanied by reduced height gain. Wu et al. further showed that among 216 children aged 5–7 years, each 1 ng/mL increase in monomethyl/ethyl phthalate (MMP/MEP) yielded a 0.01 mg/L reduction in IGFBP-3 (95% CI range: -0.003 to -0.000). Longitudinal analyses by Huang et al. confirmed an inverse association between urinary MEP and both IGF-1 ($\beta = -0.027$) and IGFBP-3 ($\beta = -0.016$). Collectively, these studies illustrate that diverse environmental toxicants consistently downregulate IGFBP-3, reinforcing the susceptibility of IGF-axis regulation to pollutant exposure and aligning with our mechanistic observations.

Mechanistic insight for inflammation and IGFBP3

PAHs in $PM_{2.5} \rightarrow CYP1A1$ activation + ROS generation $\rightarrow$ Altered IGFBP3 transcription/secretion $\rightarrow$ Disrupted IGF bioavailability $\rightarrow$ Impaired trophoblast function and fetal growth

- A growing body of evidence links inflammatory stress with IGFBP-3 suppression and highlights IGFBP-3 as an important anti-inflammatory mediator, providing mechanistic support for our PM_{2.5} findings. Clinical data from COVID-19 patients show significantly reduced circulating IGFBP-3, GH, TSH, FT3, P1NP, N-MID OC, and 25(OH)D₃ levels even in non-severe cases, suggesting that systemic inflammatory states can rapidly depress the IGF axis.
- Experimental studies in airway inflammation further demonstrate that IGFBP-3 is downregulated in bronchial epithelial cells following allergen exposure and that IGFBP-3 actively counteracts NF- κ B signaling through caspase-dependent pathways, thereby attenuating airway hyper-responsiveness.
- Similarly, in human adipocytes, IGFBP-3 inhibits TNF- α -driven NF- κ B activation and prevents inflammatory cytokine-mediated insulin resistance, implying that lower IGFBP-3 levels may exacerbate inflammatory and metabolic injury.
- Supporting this broader pattern, IL-1 β and IL-6 markedly reduce other IGF-binding proteins (IGFBP-2 and IGFBP-4) in epithelial systems, reinforcing that inflammatory cytokines broadly suppress IGFBP family members.
- Importantly, therapeutic IGF-1/IGFBP-3 administration in severely burned children restored IGF-axis levels, improved cardiac/renal/hepatic function, and significantly reduced pro-/anti-inflammatory cytokine ratios, demonstrating the capacity of IGFBP-3 to rebalance systemic inflammation in severe physiological stress.

Taken together, these studies converge on a consistent mechanism: inflammation suppresses IGFBP-3, while IGFBP-3 itself actively counter-regulates inflammatory pathways, aligning with our observation that PM_{2.5} exposure—an established inducer of oxidative and NF- κ B-mediated inflammation—leads to robust IGFBP3 repression.

References:

1. Talia C, Connolly L, Fowler PA. The insulin-like growth factor system: A target for endocrine disruptors? *Environ Int.* 2021;147:106311. doi: 10.1016/j.envint.2020.106311
2. Dai Y, Xu X, Huo X, Faas MM. Effects of polycyclic aromatic hydrocarbons (PAHs) on pregnancy, placenta, and placental trophoblasts. *Ecotoxicol Environ Saf.* 2023;262:115314. doi: 10.1016/j.ecoenv.2023.115314
3. Mahmoud AM, Wilkinson FL, Sandhu MA, Lightfoot AP. The Interplay of Oxidative Stress and Inflammation: Mechanistic Insights and Therapeutic Potential of Antioxidants. *Oxid Med Cell Longev.* 2021;2021(1). doi: 10.1155/2021/9851914
4. Gambini J, Strömsnes K. Oxidative Stress and Inflammation: From Mechanisms to Therapeutic Approaches. *Biomedicines.* 2022;10(4):753. doi: 10.3390/biomedicines10040753
5. Yuan Q, Chen Y, Li X, Zhang Z, Chu H. Ambient fine particulate matter (PM_{2.5}) induces oxidative stress and pro-inflammatory response via up-regulating the expression of CYP1A1/1B1 in human bronchial epithelial cells in vitro. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis.* 2019;839:40–8. doi: 10.1016/j.mrgentox.2018.12.005

6. Li S, Li L, Zhang C, Fu H, Yu S, Zhou M, et al. PM_{2.5} leads to adverse pregnancy outcomes by inducing trophoblast oxidative stress and mitochondrial apoptosis via KLF9/CYP1A1 transcriptional axis. *Elife*. 2023;12. doi: 10.7554/eLife.85944
7. Martín AI, Priego T, Moreno-Ruperez Á, González-Hedström D, Granado M, López-Calderón A. IGF-1 and IGFBP-3 in Inflammatory Cachexia. *Int J Mol Sci*. 2021;22(17):9469. doi: 10.3390/ijms22179469
8. Taylor AM, Bush A, Thomson A, Oades PJ, Marchant JL, Bruce-Morgan C, et al. Relation between insulin-like growth factor-I, body mass index, and clinical status in cystic fibrosis. *Arch Dis Child*. 1997;76(4):304–9. doi: 10.1136/ad.76.4.304
9. Nääv Å, Erlandsson L, Isaxon C, Åsander Frostner E, Ehinger J, Sporre MK, et al. Urban PM_{2.5} Induces Cellular Toxicity, Hormone Dysregulation, Oxidative Damage, Inflammation, and Mitochondrial Interference in the HRT8 Trophoblast Cell Line. *Front Endocrinol (Lausanne)*. 2020;11. doi: 10.3389/fendo.2020.00075
10. Huang P-C, Chang W-H, Wu M-T, Chen M-L, Wang I-J, Shih S-F, et al. Characterization of phthalate exposure in relation to serum thyroid and growth hormones, and estimated daily intake levels in children exposed to phthalate-tainted products: A longitudinal cohort study. *Environmental Pollution*. 2020;264:114648. doi: 10.1016/j.envpol.2020.114648
11. Wu W, Zhou F, Wang Y, Ning Y, Yang J-Y, Zhou Y-K. Exposure to phthalates in children aged 5–7 years: Associations with thyroid function and insulin-like growth factors. *Science of The Total Environment*. 2017;579:950–6. doi: 10.1016/j.scitotenv.2016.06.146
12. Boas M, Frederiksen H, Feldt-Rasmussen U, Skakkebaek NE, Hegedüs L, Hilsted L, et al. Childhood Exposure to Phthalates: Associations with Thyroid Function, Insulin-like Growth Factor I, and Growth. *Environ Health Perspect*. 2010;118(10):1458–64. doi: 10.1289/ehp.0901331
13. Su P-H, Chen H-Y, Chen S-J, Chen J-Y, Liou S-H, Wang S-L. Thyroid and growth hormone concentrations in 8-year-old children exposed <i>in utero</i> to dioxins and polychlorinated biphenyls. *J Toxicol Sci*. 2015;40(3):309–19. doi: 10.2131/jts.40.309
14. Street M, Miraki-Moud F, Sanderson I, Savage M, Giovannelli G, Bernasconi S, et al. Interleukin-1beta (IL-1beta) and IL-6 modulate insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells. *Journal of Endocrinology*. 2003;179(3):405–15. doi: 10.1677/joe.0.1790405
15. Lee Y-C, Jogie-Brahim S, Lee D-Y, Han J, Harada A, Murphy LJ, et al. Insulin-like Growth Factor-binding Protein-3 (IGFBP-3) Blocks the Effects of Asthma by Negatively Regulating NF-κB Signaling through IGFBP-3R-mediated Activation of Caspases. *Journal of Biological Chemistry*. 2011;286(20):17898–909. doi: 10.1074/jbc.M111.231035
16. Stuard WL, Titone R, Robertson DM. IGFBP-3 functions as a molecular switch that mediates mitochondrial and metabolic homeostasis. *The FASEB Journal*. 2022;36(1). doi: 10.1096/fj.202100710RR

Link IGFBP3 to PM via oxidative stress/PAHs; discuss synergy with KLF9/CYP1A1.

Response: We thank the reviewer for this excellent suggestion to more explicitly connect IGFBP3 dysregulation to PM_{2.5} exposure through specific mechanistic pathways and to discuss synergistic interactions with the KLF9/CYP1A1 axis. This integration substantially

strengthens the mechanistic coherence of our manuscript. We have added comprehensive sections addressing both points.

Revised text: Line 612-626

“Endocrine disruptors—including dioxins, bisphenol A, and phthalates—likewise lower IGFBP3 through ROS-dependent STAT1/NF-κB activation and promoter methylation, providing epidemiological support for pollutant-driven IGFBP3 loss(Huang *et al*, 2020; Wu *et al*, 2017; Boas *et al*, 2010; Su *et al*, 2015). IGFBP3 functions not only downstream of cytokine stress but also as a regulator of mitochondrial stability(Street *et al*, 2003; Lee *et al*, 2011). IGFBP3 depletion results in swollen, fragmented mitochondria, increased fission, reduced MFN2, elevated BNIP3L/NIX, enhanced mitophagy, suppressed mTOR activity, and reduced mtDNA—hallmarks of oxidative injury(Stuard *et al*, 2022). Thus, reduced IGFBP3 in PM_{2.5}-exposed trophoblasts likely intensifies mitochondrial destabilization initiated by PAH-activated CYP1A1. Together, these findings support a model in which PM_{2.5}-derived PAHs activate the KLF9–CYP1A1 oxidative axis, while ROS and cytokine signaling suppress IGFBP3, removing a key mitochondrial stabilizer. This synergy explains the mitochondrial dysfunction, trophoblast impairment, and placental insufficiency associated with particulate pollution exposure, positioning IGFBP3 repression as a central mechanism contributing to disrupted IGF signaling and fetal growth restriction.”

Explanation:

(The relevant points from this explanation have been concisely summarized and incorporated into the manuscript.)

In response to the reviewer's inquiry regarding mechanistic links between PM_{2.5} and IGFBP3, we propose that polycyclic aromatic hydrocarbons (PAHs)—comprising 2-15% of urban PM_{2.5}—directly regulate IGFBP3 through aryl hydrocarbon receptor (AhR) activation, with CYP1A1 serving as a critical molecular bridge via ROS generation. PAHs function as high-affinity AhR ligands in placental trophoblasts, and while putative xenobiotic response elements in IGFBP gene promoters suggest transcriptional regulation (demonstrated for IGFBP1 in dioxin-exposed cells), the directionality of AhR-IGFBP3 regulation remains context-dependent, varying by cell type, ligand specificity, stress state, and exposure duration. Concurrently, PM_{2.5}-induced oxidative stress activates stress-responsive transcription factors that further modulate IGFBP3 expression, creating a synergistic mechanism where simultaneous PAH delivery and oxidative stress produce more pronounced IGFBP3 dysregulation than either stimulus alone. This synergy extends beyond IGFBP3, as our mechanistic model demonstrates convergence of three interconnected pathways—KLF9 (regulating trophoblast differentiation- though not investigated by us but based on previous research by Li. S. et al.,), CYP1A1 (generating ROS through PAH metabolism), and IGFBP3 (modulating growth factors with IGF-independent nuclear functions)—that create a reinforcing network amplifying placental ER stress and dysfunction, explaining why PM_{2.5} exposure produces such profound placental insufficiency and suggesting that combined therapeutic approaches targeting multiple pathways may be more effective than single-target interventions.

References:

1. Huang P-C, Chang W-H, Wu M-T, Chen M-L, Wang I-J, Shih S-F, et al. Characterization of phthalate exposure in relation to serum thyroid and growth hormones, and estimated daily intake levels in children exposed to phthalate-tainted products: A longitudinal cohort study. *Environmental Pollution*. 2020;264:114648. doi: 10.1016/j.envpol.2020.114648
2. Wu W, Zhou F, Wang Y, Ning Y, Yang J-Y, Zhou Y-K. Exposure to phthalates in children aged 5–7 years: Associations with thyroid function and insulin-like growth factors. *Science of The Total Environment*. 2017;579:950–6. doi: 10.1016/j.scitotenv.2016.06.146
3. Boas M, Frederiksen H, Feldt-Rasmussen U, Skakkebaek NE, Hegedüs L, Hilsted L, et al. Childhood Exposure to Phthalates: Associations with Thyroid Function, Insulin-like Growth Factor I, and Growth. *Environ Health Perspect*. 2010;118(10):1458–64. doi: 10.1289/ehp.0901331
4. Su P-H, Chen H-Y, Chen S-J, Chen J-Y, Liou S-H, Wang S-L. Thyroid and growth hormone concentrations in 8-year-old children exposed <i>in utero</i> to dioxins and polychlorinated biphenyls. *J Toxicol Sci*. 2015;40(3):309–19. doi: 10.2131/jts.40.309
5. Street M, Miraki-Moud F, Sanderson I, Savage M, Giovannelli G, Bernasconi S, et al. Interleukin-1beta (IL-1beta) and IL-6 modulate insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells. *Journal of Endocrinology*. 2003;179(3):405–15. doi: 10.1677/joe.0.1790405
6. Lee Y-C, Jogie-Brahim S, Lee D-Y, Han J, Harada A, Murphy LJ, et al. Insulin-like Growth Factor-binding Protein-3 (IGFBP-3) Blocks the Effects of Asthma by Negatively Regulating NF-κB Signaling through IGFBP-3R-mediated Activation of Caspases. *Journal of Biological Chemistry*. 2011;286(20):17898–909. doi: 10.1074/jbc.M111.231035
7. Stuard WL, Titone R, Robertson DM. IGFBP-3 functions as a molecular switch that mediates mitochondrial and metabolic homeostasis. *The FASEB Journal*. 2022;36(1). doi: 10.1096/fj.202100710RR

Extend in the Discussion section the study's findings within the broader literature on air pollution's impact on human pregnancy. In particular, if and how results of the animal study can be translated to human situation, given pregnancy/placenta specific physiological differences.

Response: Line 668-677 & Line 680-698

We sincerely thank the reviewer for this critical observation. We have substantially expanded the Discussion section to comprehensively address both points.

“Human pregnancy is defined by prolonged gestation, advanced fetal organ maturation at birth, and a haemochorial placenta specialized for endocrine, metabolic, and immune regulation; however, no single animal model fully recapitulates all these features (Andersen *et al*, 2018). While large mammals and non-human primates offer closer anatomical similarity, their ethical, financial, and logistical constraints limit mechanistic and multi-omic interrogation (Carter, 2020). Rodent models (rat and mouse) provide a haemochorial placental interface, conserved trophoblast signaling pathways, robust genetic tractability, and experimental scalability, making them optimal discovery platforms for identifying evolutionarily conserved molecular mechanisms (Suarez *et al*, 2024; Soares *et al*, 2012; Ramdin *et al*, 2023; Aguilera *et al*, 2022). Rodents, like humans, possess a hemochorial placenta with invasive trophoblast lineages and share conserved IGF/IGFBP-regulated growth, oxidative stress susceptibility, and AhR/CYP1A1 responses to PAHs (Mason *et al*, 2011; Shynlova *et al*, 2007; Choi *et al*, 2012; Lew *et al*, 2011; Karube *et al*, 2024). These conserved features, together with supporting evidence from our human trophoblast and placental explant experiments,

strengthen the translational relevance of our observations. Nonetheless, differences in villous architecture, depth of invasion, and the temporal dynamics of placental maturation mean that our findings should not be interpreted as direct quantitative predictors of human outcomes. Rather, they reveal conserved qualitative mechanisms through which PM_{2.5} perturbs placental development.

These findings have immediate implications for clinical practice, suggesting that air quality monitoring should be integrated into prenatal care protocols, particularly in urban environments with high pollution levels. The mechanistic pathways identified in our study integrate closely with the broader epidemiological literature showing that maternal PM_{2.5} exposure impairs fetal growth, increases preeclampsia risk, and contributes to preterm birth. Large multinational meta-analyses consistently report pregnancy-averaged PM_{2.5} exposures associating with reductions in birthweight, and our findings provide molecular insight into these associations. Specifically, PM_{2.5}-induced activation of CYP1A1 generates oxidative and ER stress culminating in IGFBP3 repression, thereby impairing trophoblast function and nutrient support. Our results also align with epidemiologic studies linking PM_{2.5} to hypertensive disorders of pregnancy such as preeclampsia, where elevated TNF- α , IL-6, and IL-1 β , STAT1/NF- κ B activation, and angiogenic imbalance (reduced PlGF/VEGF with increased sFlt-1) are prominent features—molecular signatures mirrored in our model. The inflammation-driven ER-stress and apoptosis we observed similarly provide plausible biological links to the increased preterm birth risk reported in human cohorts. This work identifies ER stress as a central pathway of PM_{2.5} toxicity and positions IGFBP3 and CYP1A1 as interconnected oxidative–inflammatory–endocrine nodes governing placental vulnerability. These pathways represent potential biomarkers and therapeutic targets for high-risk pregnancies. Studies on PAHs, heavy metals, and traffic pollutants confirm that diverse PM_{2.5} components converge on similar oxidative/ER-stress mechanisms, unifying epidemiological and molecular evidence that PM_{2.5} disrupts placental development through integrated cellular injury pathways.”

References:

1. Andersen MD, Alstrup AKO, Duvald CS, Mikkelsen EFR, Vendelbo MH, Ovesen PG, et al. Animal Models of Fetal Medicine and Obstetrics. In: Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy. InTech; 2018. doi: 10.5772/intechopen.74038
2. Carter AM. Animal models of human pregnancy and placentation: alternatives to the mouse. *Reproduction*. 2020;160(6):R129–43. doi: 10.1530/REP-20-0354
3. Suarez AC, Gimenez CJ, Russell SR, Wang M, Munson JM, Myers KM, et al. Pregnancy-induced remodeling of the murine reproductive tract: a longitudinal in vivo magnetic resonance imaging study. *Sci Rep*. 2024;14(1):586. doi: 10.1038/s41598-023-50437-1
4. Soares MJ, Chakraborty D, Karim Rumi MA, Konno T, Renaud SJ. Rat placentation: An experimental model for investigating the hemochorial maternal-fetal interface. *Placenta*. 2012;33(4):233–43. doi: 10.1016/j.placenta.2011.11.026
5. Ramdin S, Baijnath S, Naicker T, Govender N. The Clinical Value of Rodent Models in Understanding Preeclampsia Development and Progression. *Curr Hypertens Rep*. 2023;25(6):77–89. doi: 10.1007/s11906-023-01233-9
6. Aguilera N, Salas-Pérez F, Ortíz M, Álvarez D, Echiburú B, Maliqueo M. Rodent models in placental research. Implications for fetal origins of adult disease. *Anim Reprod*. 2022;19(1). doi: 10.1590/1984-3143-ar2021-0134
7. Mason EJ, Grell JA, Wan J, Cohen P, Conover CA. Insulin-like growth factor (IGF)-I and IGF-II contribute differentially to the phenotype of pregnancy associated plasma protein-A knock-out mice. *Growth Hormone & IGF Research*. 2011;21(5):243–7. doi: 10.1016/j.ghir.2011.06.002

8. Shynlova O, Tsui P, Dorogin A, Langille BL, Lye SJ. Insulin-like Growth Factors and Their Binding Proteins Define Specific Phases of Myometrial Differentiation During Pregnancy in the Rat¹. *Biol Reprod.* 2007;76(4):571–8. doi: 10.1095/biolreprod.106.056929
9. Choi H, Wang L, Lin X, Spengler JD, Perera FP. Fetal Window of Vulnerability to Airborne Polycyclic Aromatic Hydrocarbons on Proportional Intrauterine Growth Restriction. *PLoS One.* 2012;7(4):e35464. doi: 10.1371/journal.pone.0035464
10. Lew BJ, Manickam R, Lawrence BP. Activation of the Aryl Hydrocarbon Receptor During Pregnancy in the Mouse Alters Mammary Development Through Direct Effects on Stromal and Epithelial Tissues¹. *Biol Reprod.* 2011;84(6):1094–102. doi: 10.1095/biolreprod.110.087544
11. Karube R, Koike M, Ikuta T, Shiizaki K. Abortion in AhR-knockout mice and fetomaternal immunity. *Reprod Biol.* 2024;24(4):100952. doi: 10.1016/j.repbio.2024.100952

Minors (All revisions have been incorporated and are marked with blue highlights throughout the manuscript)

Typographical Errors: line 56, "dimatere" should be "diameter"

Response: We truly value the feedback provided by the reviewers and have made a sincere effort to implement their suggestions. The correction has been made and highlighted. Updated Line 55.

The phrase "can breach the placental barrier and affect their function" (line 67) is unclear. It is ambiguous whether "their" refers to the placenta or pollutants. Rephrasing for clarity, e.g., "can breach the placental barrier, impairing its function," would improve readability.

Response: We thank the reviewer for the helpful suggestion. In accordance with this, the readability and overall quality of the manuscript have been improved. The recommended changes have been incorporated at Updated Lines 67–68.

Pre-2024 citations solid, but 2025 updates on PM-placenta inflammation could be enhanced.

Response: Thank you for your kind suggestion and same has been incorporated (Line 547–567).

“Recent evidence underscores that PM_{2.5} and PAH-rich air pollution exerts strong inflammatory and oxidative effects across maternal, placental, and fetal compartments (Craig *et al*, 2024; Agarwal *et al*, 2018; Dai *et al*, 2023). Elevated maternal PAH metabolites such as 1-hydroxypyrene and benzo[a]pyrene correlate with higher placental TNF- α ($p < 0.05$) and reduced IL-6, indicating a TNF- α -dominant milieu (Ferguson *et al*, 2017). Personal exposure monitoring similarly shows that each unit increase in PAH-bound PM_{2.5} corresponds to higher umbilical cord TNF- α , IL-8, and TGF- β ($p \approx 0.01–0.02$), demonstrating fetal inflammatory coupling to maternal exposure (Zhang *et al*, 2025). Prenatal NO₂ exposure associates with increased autophagy and

senescence markers (Beclin-1, $\beta \approx 0.13$, 95% CI 0.04–0.23) and elevated IL-1 β , IL-8, and MMP-9 clusters (global $p \approx 0.002$), linking pollutant stress to remodeling at birth (Gorlanova *et al*, 2025). Supporting this, the MADRES cohort found PM_{2.5}-induced enrichment of oxidative stress and inflammatory lipid pathways inversely correlated with birth weight (Chen *et al*, 2025). Experimental models parallel these findings: PM_{2.5} elevates IL-6, IL-8, and TNF- α ($p < 0.05$) and induces ROS-dependent PI3K/AKT activation, driving NF- κ B/JNK signaling, oxidative injury, and insulin resistance (Lu *et al*, 2025). Similar kinase-mediated inflammation (MKK4–JNK–AP1 axis) in keratinocytes shows that MKK4 inhibition suppresses IL-6, COX-2, and MMP-1 (Liao *et al*, 2025; Rundblad *et al*, 2025). Together, these studies reveal a conserved pattern wherein PM_{2.5}/PAHs trigger ROS accumulation, cytokine dysregulation, and stress-kinase activation that disrupt metabolic homeostasis, prime immune pathways, and compromise placental–fetal development, providing mechanistic context for pollutant-induced placental inflammation in our study (Rundblad *et al*, 2025; Liao *et al*, 2025; Yun & Kim, 2025; Lu *et al*, 2025).”

References:

1. Craig EA, Lin Y, Ge Y, Wang X, Murphy SK, Harrington DK, et al. Associations of Gestational Exposure to Air Pollution and Polycyclic Aromatic Hydrocarbons with Placental Inflammation. *Environment & Health*. 2024;2(9):672–80. doi: 10.1021/envhealth.4c00077
2. Agarwal P, Singh L, Anand M, Taneja A. Association Between Placental Polycyclic Aromatic Hydrocarbons (PAHS), Oxidative Stress, and Preterm Delivery: A Case–Control Study. *Arch Environ Contam Toxicol*. 2018;74(2):218–27. doi: 10.1007/s00244-017-0455-0
3. Dai Y, Xu X, Huo X, Faas MM. Effects of polycyclic aromatic hydrocarbons (PAHs) on pregnancy, placenta, and placental trophoblasts. *Ecotoxicol Environ Saf*. 2023;262:115314. doi: 10.1016/j.ecoenv.2023.115314
4. Ferguson KK, McElrath TF, Pace GG, Weller D, Zeng L, Pennathur S, et al. Urinary Polycyclic Aromatic Hydrocarbon Metabolite Associations with Biomarkers of Inflammation, Angiogenesis, and Oxidative Stress in Pregnant Women. *Environ Sci Technol*. 2017;51(8):4652–60. doi: 10.1021/acs.est.7b01252
5. Zhang X, Wang J, Wu Y, Li X, Zheng D, Sun L. Personal exposure to polycyclic aromatic hydrocarbons-bound particulate matter during pregnancy and umbilical inflammation and oxidative stress. *Ecotoxicol Environ Saf*. 2025;291:117896. doi: 10.1016/j.ecoenv.2025.117896
6. Gorlanova O, Oller H, Nahum U, Künstle N, Müller L, Marten A, et al. Prenatal exposure to air pollution affects autophagy, senescence and remodelling proteins in cord blood. *ERJ Open Res*. 2025;11(5):00092–2025. doi: 10.1183/23120541.00092-2025
7. Chen W, Qiu C, Hao J, Liao J, Lurmann F, Pavlovic N, et al. Maternal metabolomics linking prenatal exposure to fine particulate matter and birth weight: a cross-sectional analysis of the MADRES cohort. *Environmental Health*. 2025;24(1):14. doi: 10.1186/s12940-025-01162-x
8. Lu Y, Qiu W, Liao R, Cao W, Huang F, Wang X, et al. Subacute PM_{2.5} Exposure Induces Hepatic Insulin Resistance Through Inflammation and Oxidative Stress. *Int J Mol Sci*. 2025;26(2):812. doi: 10.3390/ijms26020812
9. Liao R, Zhang Q, Lu Y, Huang F, Cao W, Li M, et al. Fine Particulate Matter (PM_{2.5}) Disrupts Intestinal Barrier Function by Inducing Oxidative Stress and PI3K/AKT-Mediated Inflammation in Caco-2 Cells. *Int J Mol Sci*. 2025;26(17):8271. doi: 10.3390/ijms26178271
10. Rundblad A, Das S, Ginos BNR, Matthews J, Holven KB, Voortman T, et al. Exposure to fine particulate matter in adults is associated with immune cell gene expression related to inflammation, the electron transport chain, and cell cycle regulation. *Environ Epigenet*. 2025;11(1). doi: 10.1093/eep/dvaf008

11. Yun J, Kim J-E. Luteolin targets MKK4 to attenuate particulate matter-induced MMP-1 and inflammation in human keratinocytes. Sci Rep. 2025;15(1):16848. doi: 10.1038/s41598-025-01090-3

Referee #2 (Comments on Novelty/Model System for Author):

These novel studies are of high significance to human health. The article comprehensively and exhaustively examines the impact of UPM in multiple models mechanistically using "state of the art" assays and lab techniques.

Referee #2 (Remarks for Author):

Singh and colleagues report on the impact of air PM on the placenta. They note that in cell line and placental explant models, urban (UPM) increased proinflammatory cytokines and oxidative stress pathways, impairing trophoblast invasion, angiogenesis, and nutrient transport, while altering epigenetic modifications and endoplasmic reticulum function. Rodent studies revealed reduced litter size, placental abnormalities, and fetal growth arrest along with postnatal neurodevelopmental alterations. Human cohorts from high-exposure regions showed elevated low birthweight rates. Proteomic and transcriptomic analyses of rat placentae revealed an inflammatory signature and altered metabolic networks with gut microbiome dysbiosis. Transcriptomic analysis identified IGFBP3 as a major downregulated gene following UPM exposure. This reduction in IGFBP3 may be central to several placenta functions, including trophoblast migration, metabolic exchange, and vascular adaptation in uterine arteries, resulting in restricted fetal growth and altered development.

These novel studies are of high significance to human health. The article comprehensively and exhaustively examines the impact of UPM in multiple models mechanistically using "state of the art" assays and lab techniques. Controls are well thought out and there is validation of several findings such as the genomic data through TUNEL assays. There are very few published papers that have gone to the details that Singh and colleagues have to examine the biological impact of UPM exposure. One hopes the plethora of data in this study will stimulate further ex vivo research on human placentae given the important findings from this study.

I have no major comments, concerns, or suggestions. All my comments and suggestions reflect minor issues with the article and are as follows:

Author's comment: We sincerely thank the reviewer for their thoughtful and encouraging evaluation of our manuscript. We greatly appreciate the recognition of the study's significance, the strength of our multi-model experimental design, and the novelty of our mechanistic insights. The reviewer's constructive minor comments were extremely helpful in refining the clarity, accessibility, and scientific coherence of the manuscript. All suggested changes have now been fully addressed. We believe these revisions have strengthened the manuscript and improved its readability while preserving the rigor and depth of the findings.

We are grateful for the reviewer's positive assessment and for acknowledging the translational relevance of our work to human placental biology and environmental health.

* All recommended changes have been incorporated and are highlighted in yellow throughout the manuscript.

Minor comments and suggestions:

1. Line 56 – dimatere

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 55

2. Line 59 - include the reference from Narayan et al: Mandal S, Jaganathan S, Kondal D, Schwartz JD, Tandon N, Mohan V, Prabhakaran D, Narayan KMV. PM2.5 exposure, glycemic markers and incidence of type 2 diabetes in two large Indian cities. BMJ Open Diabetes Res Care. 2023 Oct;11(5):e003333. doi: 10.1136/bmjdr-2023-003333. PMID: 37797962; PMCID: PMC10565186.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 60; Mandal et al.

3. Lines 62-65 could be better reworded.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript..

4. Line 68 - insert "an" before invasive. Delete "are crucial".

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 69

5. Line 69 - insert "A" before landmark.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 70

6. Lines 79 & 383 - replace "retardation" with "restriction".

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 101 & 467

7. Line 80 - insert "A" before recent.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 126

8. Line 81 - delete "the" and insert "an underlying mechanism".

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 127

9. Line 87 - would cite the original article on the DOHaD.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 134

10. Line 97 - suggest including "and other clinical" in addition to neurobehavioral.


Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 152

11. Line 104-105 - Insert "We noted" rather than Results showed.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 162

12. Include and define Antimony (Sb) in the figure legend on P.36.

Response: We have incorporated the reviewer's suggestion, and the corresponding change is highlighted in the revised manuscript. And we have incorporated Antimony (Sb) in the figure legend as well.



13. Line 124 - insert "The" before syncytiotrophoblast.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 182

14. Italicize Latin words such as ex vivo and in vitro etc.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 184, 194, 201, 257, 259, 276, 292, 314

15. Line 141 - replace establish with "indicate".

Response: Recommended change has been made and highlighted. Updated Line 199

16. Line 148 - insert "a" substantial increase.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 206

17. Lines 153 & 256 - tissue not tissues. Tissue is plural and singular.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 211 & 316

18. Line 153 - replace "implying" with demonstrating.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 211

19. Line 178 - promotes.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 239

20. Line 201 – vis

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 261

21. Figure 4D - What is CPCB in India?

Response: We thank the reviewer for their suggestion and we carefully included the full form for CPCB. **The Central Pollution Control Board (CPCB- <https://cpcb.nic.in/>)** is India's apex organization under the Ministry of Environment, Forest and Climate Change. It is responsible for monitoring, regulating, and controlling air and water pollution, and for enforcing environmental standards nationwide. A shorter version for this has been included in the figure legend and highlighted.

22. Line 257 - write out PCA, then abbreviate.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 316

23. Line 270 - write out GSEA, then abbreviate.


Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 331

24. Line 277 - proteomic and transcriptomic data.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 337-338

25. Figure 6C - Antimony.

Response: We have incorporated the reviewer's suggestions, and the corresponding correction has been made and the image is updated.



26. Line 302 - write out ICP-MS.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 385

27. Line 355 - proteomic.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 438

28. Lines 356 & 357 pluralize placenta.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 439 & 440

29. Reword lines 357-360.

Response: Rewording of the mentioned lines have been done and highlighted. Updated Line 440-443

30. Line 383 - Replace "It's linked to adverse outcomes like" with "Associations include".

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 466

31. Line 399 - Replace disturbed with perturbed.

Response: Indicated change has been made and highlighted. Updated Line 485

32. Line 401 - write out PE.

Response: Indicated change has been made and highlighted. Updated Line 487

33. Line 403 - write out GD.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 488

34. Line 409 - Insert "the" first trimester.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 495

35. Line 409 - Insert "The" placenta.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 496

36. Line 423 - Delete "evidence".

Response: Indicated change has been made.

37. Line 432 - Insert "the" scientific literature.

Response: Indicated change has been made and highlighted. Updated Line 523

38. Line 440 - Rat not rats.

Response: Indicated change has been made and highlighted. Updated Line 532

39. Line 457 - Write out DEP.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 571

40. Line 462 - Start a new paragraph at "One of the.."

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 578

41. Line 635 - Proteomic.

Response: Indicated change has been made and highlighted. Line 800

21st Jan 2026

Dear Prof. Karmakar,

Thank you for the submission of your revised manuscript to EMBO Molecular Medicine. I am pleased to inform you that we will be able to accept your manuscript pending the following final amendments:

- 1) Please implement referee #2 suggestions.
- 2) Authors: Please provide institutional email address for the co-corresponding author Ruby Dhar in our submission system and title page of the manuscript.
- 3) Author Checklist: It seems that Source Data Checklist is uploaded instead of the Author Checklist. Please submit a complete checklist. <https://www.embopress.org/pb-assets/embo-site/EMBO%20Press%20Author%20Checklist-1642513524327.xlsx>
- 4) Figures:
 - Please upload main and EV figures as individual high-resolution files. Please check "Author Guidelines" for more information: <https://www.embopress.org/page/journal/17574684/authorguide#figureformat>
<https://www.embopress.org/page/journal/17574684/authorguide#expandedview>
 - Currently Figure 3 appears duplicated with partially redundant panels. Please clarify and correct.
 - Figure panels should be labeled A, B, C etc.
 - Make sure that each figure fits one page.
 - We note that some panels are reused between figures, e.g. Figure 1A GAPDH western blot is reused in Figure 3A, Figure 4 B1 & B3 placental tissue and fetuses reused in Figure S6. Please cite in the respective figure legend every reused image/panel.
 - In Figure EV1 Control-HTR8/SVneo cell 2 and cell 3 images seem to be overlapping areas of the same cell. Please explain and correct.
 - Please add highlight boxes to figure 5C for the 100 and 200 magnification and to figure 7C for the 4X and 10X magnification.
- 5) In the main manuscript file, please do the following:
 - Please address all comments suggested by our data editors listed below:
 - o Figure legends:
 1. Please note that the exact p values are not provided in the legends of figures 1C2, F; 3B, 4 B3, 5C, 6B, 7C, F; EV2 A.
 2. Please indicate the statistical test used for data analysis in the legends of figures 5B, EV2 A.
 3. Please note that the box plots need to be defined in terms of minima, maxima, center, bounds of box and whiskers, and percentile in the legends of figures 5C, 6C, D; 7G.
 4. Please note that information related to n is missing in the legends of figures 4 B2, D; 7F, EV1 A.
 5. Please note that the scale bar needs to be defined for figures 1 B1, B2; 7C, EV1 C.
 6. Please note that the red dotted borders are not defined in the legend of figure 1 D2. This needs to be rectified.
 - Please add callouts for Fig. S1, S3, S10, S11, S16, and Appendix Table.
 - Rename Materials and Methods should be Methods.
 - Remove Resource Availability.
 - In Methods, please include statement that the experiments involving human participants conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.
 - Move data availability statement after Acknowledgments.
 - Please rename "Competing Interest Statement" to "Disclosure and competing interests statement". We updated our journal's competing interests policy in January 2022 and request authors to consider both actual and perceived competing interests. Please review the policy <https://www.embopress.org/competing-interests> and update your competing interests if necessary.
 - Author contributions: Please remove it from the manuscript and specify author contributions in our submission system. CRediT has replaced the traditional author contributions section because it offers a systematic machine-readable author contributions format that allows for more effective research assessment. You are encouraged to use the free text boxes beneath each contributing author's name to add specific details on the author's contribution. More information is available in our guide to authors: <https://www.embopress.org/page/journal/17574684/authorguide#authorshipguidelines>
 - Please merge it with Acknowledgements.
- 6) Funding: Please merge it with Acknowledgements.
- 7) Appendix:
 - Please upload as PDF file.
 - Add page numbers to the table of content.
 - Move all material and methods to the main Methods section.
 - Rename figures and tables to Appendix Figure S1, etc, Appendix Table S1, etc. Update their callouts in the main manuscript file.
 - Rename SI References to Appendix Reference
- 8) Synopsis:
 - Synopsis image: Please simplify the image and upload it as a separate high-resolution .jpeg/.png file 550 px-wide x 300-600 pixels high. Remove it from the manuscript file.
 - Synopsis text: Please remove it from the manuscript file and upload it as a separate .doc file.
 - Please check your synopsis text and image before submission with your revised manuscript. Please be aware that in the proof

stage minor corrections only are allowed (e.g., typos).

9) As part of the EMBO Publications transparent editorial process (see our Editorial at <http://embomolmed.embopress.org/content/2/9/329>), EMBO Molecular Medicine will publish online a Review Process File (RPF) to accompany accepted manuscripts. This file will be published in conjunction with your paper and will include the anonymous referee reports, your point-by-point response and all pertinent correspondence relating to the manuscript. Let us know if you want to remove or not any figures from it prior to publication. Please note that the Authors checklist will be published at the end of the RPF.

10) Please provide a point-by-point letter INCLUDING my comments as well as the reviewer's reports and your detailed responses (as Word file).

I look forward to reading a new revised version of your manuscript as soon as possible.

Yours sincerely,

Zeljko Durdevic

Zeljko Durdevic
Senior Editor
EMBO Molecular Medicine

*** Instructions to submit your revised manuscript ***

*** PLEASE NOTE *** As part of the EMBO Publications transparent editorial process initiative (see our Editorial at <https://www.embopress.org/doi/pdf/10.1002/emmm.201000094>), EMBO Molecular Medicine will publish online a Review Process File to accompany accepted manuscripts.

In the event of acceptance, this file will be published in conjunction with your paper and will include the anonymous referee reports, your point-by-point response and all pertinent correspondence relating to the manuscript. If you do NOT want this file to be published, please inform the editorial office at contact@embomolmed.org.

When preparing your revised manuscript, please refer to our guidelines: <https://link.springer.com/journal/44321/submission-guidelines#cms-Revised-submissions>. We perform an initial quality control of all revised manuscripts before re-review; failure to include requested items will delay the evaluation of your revision.

We require:

1) A .docx formatted version of the manuscript text (including legends for main figures, EV figures and tables). Please make sure that the changes are highlighted to be clearly visible.

2) Individual production quality figure files as .eps, .tif, .jpg (one file per figure). For guidance, download the 'Figure Guide PDF': <https://media.springernature.com/original/springer-cms/rest/v1/content/27825798/data/v1>.

3) A .docx formatted letter INCLUDING the reviewers' reports and your detailed point-by-point responses to their comments. As part of the EMBO Press transparent editorial process, the point-by-point response is part of the Review Process File (RPF), which will be published alongside your paper.

4) A complete author checklist, which you can download from our author guidelines. Please insert information in the checklist that is also reflected in the manuscript. The completed author checklist will also be part of the RPF.

5) Please note that all corresponding authors are required to supply an ORCID ID for their name upon submission of a revised manuscript.

6) It is mandatory to include a 'Data Availability' section after the Materials and Methods. Before submitting your revision, primary datasets produced in this study need to be deposited in an appropriate public database, and the accession numbers and database listed under 'Data Availability'. Please remember to provide a reviewer password if the datasets are not yet public.

In case you have no data that requires deposition in a public database, please state so in this section. Note that the Data Availability Section is restricted to new primary data that are part of this study.

7) For data quantification: please specify the name of the statistical test used to generate error bars and P values, the number (n) of independent experiments (specify technical or biological replicates) underlying each data point and the test used to calculate p-values in each figure legend. The figure legends should contain a basic description of n, P and the test applied. Graphs must include a description of the bars and the error bars (s.d., s.e.m.).

8) At EMBO Press we ask authors to provide source data for the main manuscript figures. You will receive a separate email with instructions for providing source data with your revised manuscript, including how to upload and organize the files.

9) Our journal encourages inclusion of *data citations in the reference list* to directly cite datasets that were re-used and obtained from public databases. Data citations in the article text are distinct from normal bibliographical citations and should directly link to the database records from which the data can be accessed. In the main text, data citations are formatted as follows: "Data ref: Smith et al, 2001" or "Data ref: NCBI Sequence Read Archive PRJNA342805, 2017". In the Reference list, data citations must be labeled with "[DATASET]". A data reference must provide the database name, accession number/identifiers and a resolvable link to the landing page from which the data can be accessed at the end of the reference.

10) We replaced Supplementary Information with Expanded View (EV) Figures and Tables that are collapsible/expandable online. A maximum of 5 EV Figures can be typeset. EV Figures should be cited as 'Figure EV1, Figure EV2' etc... in the text and their respective legends should be included in the main text after the legends of regular figures.

- For the figures that you do NOT wish to display as Expanded View figures, they should be bundled together with their legends in a single PDF file called *Appendix*, which should start with a short Table of Content. Appendix figures should be referred to in the main text as: "Appendix Figure S1, Appendix Figure S2" etc.

- Additional Tables/Datasets should be labeled and referred to as Table EV1, Dataset EV1, etc. Legends have to be provided in a separate tab in case of .xls files. Alternatively, the legend can be supplied as a separate text file (README) and zipped together with the Table/Dataset file.

11) The paper explained: EMBO Molecular Medicine articles are accompanied by a summary of the articles to emphasize the major findings in the paper and their medical implications for the non-specialist reader. Please provide a draft summary of your article highlighting

- the medical issue you are addressing,
- the results obtained and
- their clinical impact.

This may be edited to ensure that readers understand the significance and context of the research. Please refer to any of our published articles for an example.

12) Author contributions: You will be asked to provide CRediT (Contributor Role Taxonomy) terms in the submission system. These replace a narrative author contribution section in the manuscript.

13) A Conflict of Interest statement should be provided in the main text.

14) Every published paper includes a 'Synopsis' to further enhance discoverability. Synopses are displayed on the journal webpage and are freely accessible to all readers. They include a short stand first (maximum of 300 characters, including space) as well as 2-5 one-sentences bullet points that summarizes the paper. Please write the bullet points to summarize the key NEW findings. They should be designed to be complementary to the abstract - i.e. not repeat the same text. We encourage inclusion of key acronyms and quantitative information (maximum of 30 words / bullet point). Please use the passive voice. Please attach these in a separate file or send them by email, we will incorporate them accordingly.

Please also suggest a striking image or visual abstract to illustrate your article as a PNG file 550 px wide x 300-600 px high.

15) Include a Reagents and Tools Table as part of the Methods section, which can be downloaded from our author guidelines.

EMBO Molecular Medicine has a "scooping protection" policy, whereby similar findings that are published by others during review or revision are not a criterion for rejection. Should you decide to submit a revised version, I do ask that you get in touch after three months if you have not completed it, to update us on the status.

*Additional important information regarding Figures

Each figure should be given in a separate file and should have the following resolution:

Graphs 800-1,200 DPI

Photos 400-800 DPI

Colour (only CMYK) 300-400 DPI"

Figures are not edited by the production team. All lettering should be the same size and style; figure panels should be indicated by capital letters (A, B, C etc). Gridlines are not allowed except for log plots. Figures should be numbered in the order of their appearance in the text with Arabic numerals. Each Figure must have a separate legend and a caption is needed for each panel.

*Additional important information regarding figures and illustrations can be found at

<https://media.springernature.com/original/springer-cms/rest/v1/content/27825798/data/v1>

***** Reviewer's comments *****

Referee #1 (Comments on Novelty/Model System for Author):

Authors responded to all comments adequately and included most of the suggestions sufficiently.

Referee #2 (Comments on Novelty/Model System for Author):

This is a re-review. The authors have adequately addressed my concerns and those from Reviewer 1. I only have minor edits for the author, below.

Referee #2 (Remarks for Author):

The authors have addressed the concerns from both reviewers. In the current draft please address the following:

1. Line 64 landmark
2. Line 103 replace "and" with "while".
3. Line 112 replace "have" with "has".
4. Line 119 - write out PE.
5. Line 139 - write out MMP-2.
6. Line 146 - the fetus. Delete "and remains to be explored".
7. Line 230 - replace "have" with "has".
8. Line 294, 743, & 747 - replace Deogarh with Deoghar. Deogarh can be found in UP, Odisha, and Rajasthan, but not in Jharkhand.
9. Line 296 - Delete "have".
10. Lines 298 and 299 - insert "for the incidence of low birth weight."
11. Lines 340 & 353- italicize "in-utero".
12. Line 399 - italicize *Helicobacter pylori*.
13. Line 472 - placenta.
14. Line 483 - delete "few discussed mechanisms".
15. Line 485 - Harmonize PM. Either refer to PM as PM2.5, PM10 etc or as PM2.5, PM10 etc throughout the manuscript.
16. Line 547 - Diesel Exhaust Particle (DEP) exposure.
17. Line 669 - replace associating with associated.
18. Lines 669-670 - reword as follows: associated with reductions in birthweight. Our findings provide molecular insight into these associations.
19. Line 715: Behavioural - Use either behavioural (UK) or behavioral (US) but not both in the manuscript.
20. Line 785 - Placental.
21. Line 845 - Italicize *In situ*.

Response to Editor's comments

We thank you for your encouraging decision and for the opportunity to submit the final amended version of our manuscript for publication in *EMBO Molecular Medicine*. We are grateful for the detailed editorial feedback and for considering our work acceptable pending these final revisions.

We have carefully implemented all requested amendments and revised the manuscript accordingly. A point-by-point summary of the changes is provided below.

1) Please implement referee #2 suggestions.

Response: We are thankful to the editor for their time and consideration. We have addressed the suggestions recommended by the referee #2.

2) Authors: Please provide institutional email address for the co-corresponding author Ruby Dhar in our submission system and title page of the manuscript.

Response: We have included the institutional email address for co-corresponding author.

3) Author Checklist: It seems that Source Data Checklist is uploaded instead of the Author Checklist. Please submit a complete checklist. <https://www.embopress.org/pb-assets/embo-site/EMBO%20Press%20Author%20Checklist-1642513524327.xlsx>

Response: We thank the editor for pointing this out. Due to an oversight during the previous submission, the Source Data Checklist was inadvertently uploaded in place of the Author Checklist. We have now uploaded the complete and correct Author Checklist using the official EMBO Press template, as requested.

4)Figures:

- Please upload main and EV figures as individual high-resolution files. Please check "Author Guidelines" for more information:

<https://www.embopress.org/page/journal/17574684/authorguide#figureformat> <https://www.embopress.org/page/journal/17574684/authorguide#expandedview>

Response: We have uploaded all main and Expanded View (EV) figures as individual high-resolution files in accordance with the EMBO Press Author Guidelines. All figures have been prepared to meet the required formatting and resolution criteria.

- Currently Figure 3 appears duplicated with partially redundant panels. Please clarify and correct.

Response: We thank the editor for the opportunity to clarify this point. The GAPDH blot was initially reused from Figure 1 because the same membrane was stripped after the first protein detection and then re-probed for ER stress markers, which resulted in identical GAPDH loading controls. To avoid any possible confusion, we have now replaced the reused GAPDH blot with another GAPDH blot from the same experimental set. Figure 3 has been corrected accordingly, and the updated blot is included in the revised manuscript, accurately representing the original data.

- Figure panels should be labeled A, B, C etc.

Response: We thank the editor for this suggestion. All figure panels have now been clearly labelled as A, B, C, etc., and the figures have been updated accordingly in the revised manuscript.

- Make sure that each figure fits one page.

Response: We have followed the figure dimension guidelines for submission and have adjusted all figures accordingly to ensure that each figure fits within a single page.

- We note that some panels are reused between figures, e.g. Figure 1A GAPDH western blot is reused in Figure 3A. Figure 4 B1 & B3 placental tissue and fetuses reused in Figure S6. Please cite in the respective figure legend every reused image/panel.

Response: We thank the editor for drawing attention to this point. The reuse of the blot in Figure 3A has been addressed and justified previously, and the figure has now been corrected such that no ambiguity remains.

Regarding Figures 4B1 and 4B3 (relabelled as 4B and 4D), the reuse of representative images was intentional and aimed at displaying replicates derived from the same experimental cohort. Specifically, these panels illustrate the uterine horns and corresponding fetuses collected from three independent dams, allowing visualization of gross morphological differences between control and UPM-exposed groups across gestation. To further strengthen transparency, two additional independent biological replicates were included in the Appendix figure, representing data from two separate experimental sets along with the image for one replicate which was already used in main manuscript.

To ensure clarity and avoid any potential confusion, we have explicitly cited the reuse of images in the legend of Supplementary Figure S6, as follows: *"Images of placental tissue and fetuses shown at GD21.5 are reused in the main manuscript Figures 4B and 4D, respectively, and are referenced here for continuity and comparative visualization across gestational stages."*

All reused panels are now clearly cited in their respective figure legends, and the manuscript has been revised accordingly to address any potential confusion.

- In Figure EV1 Control-HTR8/SVneo cell 2 and cell 3 images seem to be overlapping areas of the same cell.

Please explain and correct.



Response: We thank the editor for noting this issue. We apologise that the overlap between Control HTR8/SVneo cell images 2 and 3 in Figure EV1 resulted due to the bigger sizes of TEM images used during figure assembly. To correct this, we have now replaced the overlapping panel with a new representative control image, ensuring that all images shown are derived from distinct cells. Figure EV1 has been updated accordingly. This correction does not affect the results, interpretation, or conclusions of the study.

- Please add highlight boxes to figure 5C for the 100 and 200 magnification and to figure 7C for the 4X and 10X magnification.

Response: We thank the editor for this suggestion. In Figure 5C, we have now included highlight boxes indicating the regions shown at higher magnification. The 10× control image and its corresponding magnified area, as well as the 10× UPM image and its corresponding magnified area, are now placed together to facilitate clearer visual comparison.


Similarly, in Figure 7C, highlight boxes have been added to indicate the regions corresponding to the 4× and 10× magnifications. These modifications improve figure clarity and readability.

Old Figure:



Corrected Figure 5C now is 5F:

Corrected Figure 7



5) In the main manuscript file, please do the following:


- Please address all comments suggested by our data editors listed below:

o Figure legends:


1. Please note that the exact p values are not provided in the legends of figures 1C2, F; 3B, 4B3, 5C, 6B, 7C, F; EV2 A.

Response: We thank the editor for pointing this out. The **exact p values have now been added to the figures** for Figures 1C2->1E, 1F->1J, 3B, 4B3->4D, 5C->5F, 6B, 7C, 7F, and EV2A, and the manuscript has been corrected accordingly.

Old images with $p < 0.0001$



Corrected images can be found at their updated positions 1E, 1J, 3B, 4D, 5F, 6B, 7C, 7F and EV2 A



2. Please indicate the statistical test used for data analysis in the legends of figures 5B, EV2A.

Response: We thank the editor for this suggestion. Figure 5B is the data of transcriptomic analysis and hence the analysis summary has been included in the figure legend. The statistical tests used for data analysis have now been indicated in the figure legends for EV2A. These additions have been highlighted in green in the revised manuscript for ease of identification.

3. Please note that the box plots need to be defined in terms of minima, maxima, center, bounds of box and whiskers, and percentile in the legends of figures 5C, 6C, D; 7G.

Response: We thank the editor for this comment. The definitions of the box plots, including minima, maxima, centre, have now been added to the figure legends for Figures 5C→5F, 6C, 6D, and 7G. These additions have been highlighted in green in the revised manuscript for clarity. For Figures 6C and 6D, a single common description has been provided at the end of the legend to avoid redundancy.

4. Please note that information related to n is missing in the legends of figures 4 B2, D; 7F, EV1 A.

Response: We thank the editor for pointing this out. The information related to sample size (n) has now been added to the figure legends for Figures 4B2→C, 4D, 7F, and EV1A, and these additions have been highlighted in green in the revised manuscript for clarity.

We would also like to clarify that the sample size reported for Figure 4B (*GD16.5*: control $n = 72$, *UPM* $n = 62$; *GD21.5*: control $n = 74$, *UPM* $n = 55$) is identical across panels B1→B, B2→C, and B3→D, as these panels are derived from the same experimental cohorts. So to avoid the redundancy we have written the sample size at the end of 4D in figure legend.

5. Please note that the scale bar needs to be defined for figures 1 B1, B2; 7C, EV1 C.

Response: We thank the editor for noting this. The scale bars have now been defined in the figure legends for Figures 1B1->1B, 1B2->1C, 7C, and EV1C. These additions have been highlighted in the revised manuscript for clarity.

6. Please note that the red dotted borders are not defined in the legend of figure 1 D2. This needs to be rectified.

Response: We thank the editor for pointing this out. The red dotted borders have now been defined in the figure legend of Figure 1D2->1G. This correction has been highlighted in green in the revised manuscript for clarity.

- Please add callouts for Fig. S1, S3, S10, S11, S16, and Appendix Table.

Response: We thank the editor for this suggestion. The callouts for Figures S1, S3, S10, S11, S16, and the Appendix Table have now been added at the appropriate locations in the manuscript. These additions have been highlighted in green in the revised version for clarity.

- Rename Materials and Methods should be Methods.

Response: We thank the editor for this suggestion. The correction has been implemented.

- Remove Resource Availability.

Response: We thank the editor for this suggestion. The correction has been implemented.

- In Methods, please include statement that the experiments involving human participants conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.

Response: We thank the editor for this suggestion. The mentioned lines have been included in the method section and highlighted as green.

- Move data availability statement after Acknowledgments.

Response: We thank the editor for this suggestion. The correction has been implemented.

- Please rename "Competing Interest Statement" to "Disclosure and competing interests statement". We updated our journal's competing interests policy in January 2022 and request authors to consider both actual and perceived competing interests. Please review the policy <https://www.emboopen.org/competing-interests> and update your competing interests if necessary.

Response: We thank the editor for this suggestion. The correction has been implemented.

- Author contributions: Please remove it from the manuscript and specify author contributions in our submission system. CRediT has replaced the traditional author contributions section because it offers a systematic machine-readable author contributions format that allows for more effective research assessment. You are encouraged to use the free text boxes beneath each contributing author's name to add specific details on the author's contribution. More information is available in our guide to authors: <https://www.ambopress.org/page/journal/17574684/authorguide/authorshipguidelines>.

Response: We thank the editor for this suggestion. The correction has been implemented.

6) Funding: Please merge it with Acknowledgements.

Response: We thank the editor for this suggestion. The correction has been implemented.

7) Appendix:

- Please upload is as PDF file.

Response: We thank the editor for this suggestion. We have now uploaded a corrected pdf for appendix.

- Add page numbers to the table of content.

Response: We thank the editor for this suggestion. The correction has been implemented.

- Move all material and methods to the main Methods section.

Response: We thank the editor for this suggestion. The correction has been implemented.

- Rename figures and tables to Appendix Figure S1, etc, Appendix Table S1, etc. Update their callouts in the main manuscript file.

Response: We thank the editor for this suggestion. The correction has been implemented.

- Rename SI References to Appendix Reference

Response: We thank the editor for this suggestion. Following the corrections to the appendix file, the previously included references were removed, and as such, references are no longer required to be placed in the appendix.

8) Synopsis:

- Synopsis image: Please simplify the image and upload it as a separate high-resolution .jpeg/.png file 550 px-wide x 300-600 pixels high. Remove it from the manuscript file.
- Synopsis text: Please remove it from the manuscript file and upload it as a separate .doc file.
- Please check your synopsis text and image before submission with your revised manuscript. Please be aware that in the proof stage minor corrections only are allowed (e.g., typos).

9) As part of the EMBO Publications transparent editorial process (see our Editorial at <http://embomolmed.embopress.org/content/2/9/329>), EMBO Molecular Medicine will publish online a Review Process File (RPF) to accompany accepted manuscripts. This file will be published in conjunction with your paper and will include the anonymous referee reports, your point-by-point response and all pertinent correspondence relating to the manuscript. Let us know if you want to remove or not any figures from it prior to publication. Please note that the Authors checklist will be published at the end of the RPF.

10) Please provide a point-by-point letter INCLUDING my comments as well as the reviewer's reports and your detailed responses (as Word file).

Referee #2 (Comments on Novelty/Model System for Author):

We thank Referee #2 for their positive assessment of the revised manuscript and for noting that the concerns from both reviewers have been addressed. We appreciate the remaining comments and have carefully incorporated the requested revisions. A point-by-point response is provided below. All the incorporated changes have been highlighted in yellow for their better navigation.

Referee #2 (Remarks for Author):

The authors have addressed the concerns from both reviewers. In the current draft please address the following:

1. Line 64 landmark

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript.

2. Line 103 replace "and" with "while".

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript.

3. Line 112 replace "have" with "has".

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript.

4. Line 119 - write out PE.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript.

5. Line 139 - write out MMP-2.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript.

6. Line 146 - the fetus. Delete "and remains to be explored".

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 147

7. Line 230 - replace "have" with "has".

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 233

8. Line 294, 743, & 747 - replace Deogarh with Deoghar. Deogarh can be found in UP, Odisha, and Rajasthan, but not in Jharkhand.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated throughout the manuscript.

9. Line 296 - Delete "have".

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 303

10. Lines 298 and 299 - insert "for the incidence of low birth weight."

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 305

11. Lines 340 & 353- italicize "in-utero".

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 349 and 363

12. Line 399 - italicize *Helicobacter pylori*.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 408

13. Line 472 - placenta.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 484

14. Line 483 - delete "few discussed mechanisms".

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 494

15. Line 485 - Harmonize PM. Either refer to PM as PM_{2.5}, PM₁₀ etc or as PM_{2.5}, PM₁₀ etc throughout the manuscript.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Throughout the manuscript, we have used the term UPM specifically in sections describing our experimental findings. In sections that refer to previously

published studies, particulate matter is explicitly denoted as PM_{2.5} or PM₁₀, in accordance with the cited literature. In the introductory section, we initially use the general term PM to introduce particulate matter, after which the terminology is used consistently and specified as PM_{2.5} or PM₁₀ as appropriate.

16. Line 547 - Diesel Exhaust Particle (DEP) exposure.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 560

17. Line 669 - replace associating with associated.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 668

18. Lines 669-670 - reword as follows: associated with reductions in birthweight. Our findings provide molecular insight into these associations.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 683-684

19. Line 715: Behavioural - Use either behavioural (UK) or behavioral (US) but not both in the manuscript.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated throughout the manuscript.

20. Line 785 - Placental.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 882

21. Line 845 - Italicize In situ.

Response: We have incorporated the reviewer's suggestions, and the corresponding changes are highlighted in the revised manuscript. Updated Line 967

20th Feb 2026

Dear Prof. Karmakar,

We are pleased to inform you that your manuscript is accepted for publication and is now being sent to our publisher to be included in the next available issue of EMBO Molecular Medicine.

Your manuscript will be processed for publication by EMBO Press. It will be copy edited and you will receive page proofs prior to publication. Please note that you will be contacted by Springer Nature Author Services to complete licensing and payment information.

You may qualify for financial assistance for your publication charges - either via a Springer Nature fully open access agreement or an EMBO initiative. Check your eligibility: <https://link.springer.com/journal/44321/how-to-publish-with-us>

Should you be planning a Press Release on your article, please get in contact with embo_production@springernature.com as early as possible in order to coordinate publication and release dates.

If you have any questions, please do not hesitate to contact the Editorial Office. Thank you for your contribution to EMBO Molecular Medicine.

Yours sincerely,
Zeljko Durdevic

Zeljko Durdevic
Senior Editor
EMBO Molecular Medicine

>>> Please note that it is EMBO Molecular Medicine policy for the transcript of the editorial process (containing referee reports and your response letter) to be published as an online supplement to each paper. If you do NOT want this, you will need to inform the Editorial Office via email immediately. More information is available here: <https://link.springer.com/partners/embo-press/editorial-policies#Peer%20review>

EMBO Press Author Checklist

Corresponding Author Name: Subhradip Karmakar
Journal Submitted to: EMBO Molecular Medicine
Manuscript Number: EMM-2025-22578

USEFUL LINKS FOR COMPLETING THIS FORM

[The EMBO Journal - Author Guidelines](#)
[EMBO Reports - Author Guidelines](#)
[Molecular Systems Biology - Author Guidelines](#)
[EMBO Molecular Medicine - Author Guidelines](#)

Reporting Checklist for Life Science Articles (updated January

This checklist is adapted from Materials Design Analysis Reporting (MDAR) Checklist for Authors. MDAR establishes a minimum set of requirements in transparent reporting in the life sciences (see Statement of Task: [10.31222/osf.io/9sm4x](#)). Please follow the journal's guidelines in preparing your

Please note that a copy of this checklist will be published alongside your article.

Abridged guidelines for figures

1. Data

The data shown in figures should satisfy the following conditions:

- the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner.
- ideally, figure panels should include only measurements that are directly comparable to each other and obtained with the same assay.
- plots include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical
- if n<5, the individual data points from each experiment should be plotted. Any statistical test employed should be justified.
- Source Data should be included to report the data underlying figures according to the guidelines set out in the authorship guidelines on Data

2. Captions

Each figure caption should contain the following information, for each panel where they are relevant:

- a specification of the experimental system investigated (eg cell line, species name).
- the assay(s) and method(s) used to carry out the reported observations and measurements.
- an explicit mention of the biological and chemical entity(ies) that are being measured.
- an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
- the exact sample size (n) for each experimental group/condition, given as a number, not a range;
- a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
- a statement of how many times the experiment shown was independently replicated in the laboratory.
- definitions of statistical methods and measures:
 - common tests, such as t-test (please specify whether paired vs. unpaired), simple χ^2 tests, Wilcoxon and Mann-Whitney tests, can be unambiguously identified by name only, but more complex techniques should be described in the methods section;
 - are tests one-sided or two-sided?
 - are there adjustments for multiple comparisons?
 - exact statistical test results, e.g., P values = x but not P values < x;
 - definition of 'center values' as median or average;
 - definition of error bars as s.d. or s.e.m.

Please complete ALL of the questions below.

Select "Not Applicable" only when the requested information is not relevant for your study.

Materials

Newly Created Materials	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
New materials and reagents need to be available; do any restrictions apply?	Yes	Methods
Antibodies	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
For antibodies provide the following information: - Commercial antibodies: RRID (if possible) or supplier name, catalogue number and or/clone number - Non-commercial: RRID or citation	Yes	Reagents and Tools Table
DNA and RNA sequences	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Short novel DNA or RNA including primers, probes: provide the sequences.	Yes	Reagents and Tools Table
Cell materials	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, and/ OR RRID.	Yes	Reagents and Tools Table
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	Not Applicable	
Report if the cell lines were recently authenticated (e.g., by STR profiling) and tested for mycoplasma contamination.	Not Applicable	
Experimental animals	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Laboratory animals or Model organisms: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID.	Yes	Reagents and Tools Table, Methods
Animal observed in or captured from the field: Provide species, sex, and age where possible.	Not Applicable	
Please detail housing and husbandry conditions .	Yes	Appendix
Plants and microbes	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Plants: provide species and strain, ecotype and cultivar where relevant, unique accession number if available, and source (including location for collected wild specimens).	Not Applicable	
Microbes: provide species and strain, unique accession number if available, and source.	Not Applicable	
Human research participants	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
If collected and within the bounds of privacy constraints report on age, sex and gender or ethnicity for all study participants.	Yes	Figures
Core facilities	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
If your work benefited from core facilities, was their service mentioned in the acknowledgments section?	Yes	Acknowledgement and Methods

Design

Study protocol	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
If study protocol has been pre-registered , provide DOI in the manuscript . For clinical trials, provide the trial registration number OR cite DOI.	Not Applicable	
Report the clinical trial registration number (at ClinicalTrials.gov or equivalent), where applicable.	Not Applicable	

Laboratory protocol	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Provide DOI OR other citation details if external detailed step-by-step protocols are available.	Yes	Methods

Experimental study design and statistics	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Include a statement about sample size estimate even if no statistical methods were used.	Yes	Methods
Were any steps taken to minimize the effects of subjective bias when allocating animals/samples to treatment (e.g. randomization procedure)? If yes, have they been described?	Not Applicable	
Include a statement about blinding even if no blinding was done.	Not Applicable	
Describe inclusion/exclusion criteria if samples or animals were excluded from the analysis. Were the criteria pre-established?	Yes	Methods
If sample or data points were omitted from analysis, report if this was due to attrition or intentional exclusion and provide justification.		
For every figure, are statistical tests justified as appropriate? Do the data meet the assumptions of the tests (e.g., normal distribution)? Describe any methods used to assess it. Is there an estimate of variation within each group of data? Is the variance similar between the groups that are being statistically compared?	Yes	Methods

Sample definition and in-laboratory replication	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
In the figure legends: state number of times the experiment was replicated in laboratory.	Yes	Figures
In the figure legends: define whether data describe technical or biological replicates .	Yes	Figures

Ethics

Ethics	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Studies involving human participants : State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Yes	Acknowledgement
Studies involving human participants : Include a statement confirming that informed consent was obtained from all subjects and that the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.	Yes	Methods
Studies involving human participants : For publication of patient photos , include a statement confirming that consent to publish was obtained.	Not Applicable	
Studies involving experimental animals : State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. Include a statement of compliance with ethical regulations.	Yes	Methods
Studies involving specimen and field samples : State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Yes	Methods

Dual Use Research of Concern (DURC)	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Could your study fall under dual use research restrictions? Please check biosecurity documents and list of select agents and toxins (CDC): https://www.selectagents.gov/sat/list.htm .	Not Applicable	
If you used a select agent, is the security level of the lab appropriate and reported in the manuscript?	Not Applicable	
If a study is subject to dual use research of concern regulations, is the name of the authority granting approval and reference number for the regulatory approval provided in the manuscript?	Not Applicable	

Reporting

The MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.

Adherence to community standards	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
State if relevant guidelines or checklists (e.g., ICMJE, MIBBI, ARRIVE, PRISMA) have been followed or provided.	Not Applicable	
For tumor marker prognostic studies , we recommend that you follow the REMARK reporting guidelines (see link list at top right). See author guidelines, under 'Reporting Guidelines'. Please confirm you have followed these guidelines.	Not Applicable	
For phase II and III randomized controlled trials , please refer to the CONSORT flow diagram (see link list at top right) and submit the CONSORT checklist (see link list at top right) with your submission. See author guidelines, under 'Reporting Guidelines'. Please confirm you have submitted this list.	Not Applicable	

Data Availability

Data availability	Information included in the manuscript?	In which section is the information available? (Reagents and Tools Table, Materials and Methods, Figures, Data Availability Section)
Have primary datasets been deposited according to the journal's guidelines (see 'Data Deposition' section) and the respective accession numbers provided in the Data Availability Section?	Yes	Data Availability Section
Were human clinical and genomic datasets deposited in a public access-controlled repository in accordance to ethical obligations to the patients and to the applicable consent agreement?	Not Applicable	
Are computational models that are central and integral to a study available without restrictions in a machine-readable form? Were the relevant accession numbers or links provided?	Not Applicable	
If publicly available data were reused, provide the respective data citations in the reference list .	Yes	Figure and References